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Zusammenfassung 
Trotz diverser Fortschritte in der Behandlung von Lungenkrebs, führen maligne 
Lungentumore weiterhin die Liste der Tumor-assoziierten Todesfälle an. Mit einer 
5-Jahres Überlebensrate von 15,9% gehört Lungenkrebs immer noch zu den 
Krankheiten mit der höchsten Mortalität weltweit. Da eine frühzeitige Erkennung 
von Lungentumoren weiterhin schwierig ist, ist auch eine frühzeitige Behandlung 
vielfach nicht möglich. Ein Schwerpunkt in der Entwicklung von neuen Therapien 
für Tumorerkrankungen in den letzten Jahren liegt daher zum Einen auf der Be-
handlung des tumorumgebenden Milieus, das aus verschiedenen Zellarten be-
steht. Gerade Tumorassoziierte Makrophagen spielen darin eine wichtige Rolle 
und sind in den letzten Jahren in den Fokus möglicher Therapien gerückt. Zum 
Anderen wurden vermehrt Studien zu zielgerichteten Therapien durchgeführt. 
Die Idee ist, spezifisch nur Tumorzellen oder Zellen des tumorumgebenden Mili-
eus zu eliminieren und so gesundes Gewebe zu schonen und Nebenwirkungen 
zu reduzieren. Eine Möglichkeit solch einer zielgerichteten Therapie ist ein Na-
nopartikel-basierter Therapieansatz. Die Nanometer großen Partikel bestehen 
aus unterschiedlichsten organischen und anorganischen Materialien und können 
z.B. so entwickelt werden, dass eingeschlossene Chemotherapeutika nur auf be-
stimmte Stimuli hin entweichen können. Außerdem können Liganden angebracht 
werden, die an bestimmte nur auf den Zielzellen exprimierte Rezeptoren binden, 
und so eine rezeptorspezifische Aufnahme der Nanotherapeutika in den Zielzel-
len sicherstellen.  
Unsere Kooperationspartner haben zu diesem Zweck mesoporöse Siliziumnano-
partikel (MSNs) entwickelt, aus denen die eingeschlossenen Therapeutika nur im 
sauren Milieu entweichen können. Zudem wurden Liganden befestigt, die spezi-
fisch mit Rezeptoren auf Lungenkarzinomzellen reagieren und so eine Rezeptor-
gesteuerte Aufnahme der MSNs in die Zielzellen erwirken können. Das Ziel der 
vorliegenden Arbeit war die Evaluation von zielgerichteten MSNs, die an den 
CCR2 Rezeptor binden, der vor allem auf Lungenkarzinomzellen und Tumoras-
soziierten Makrophagen von Lungenkarzinompatienten über-exprimiert ist.  
Zur Beurteilung der genannten Partikel wurde ein Studiendesign mit in vitro, ex 
vivo und in vivo Experimenten entwickelt. Zunächst konnten wir feststellen, dass 
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der CCR2 Rezeptor sowohl in humanen Lungenkarzinomproben, als auch in Tu-
moren des K-rastm3Tyj Maus Modells, ein etabliertes Tiermodell für Lungenkarzi-
nome, über-exprimiert ist. Zudem nahmen CCR2 exprimierende MHS Zellen die 
zielgerichteten Nanopartikel deutlich stärker auf, als ungerichtete Kontrollpartikel. 
Die Ergebnisse eines ex vivo Ansatzes, bei dem vitale Lungensektionen aus K-
rastm3Tyj Maus Lungen mit MSNs behandelt wurden, konnten auf Grund von ex-
perimentellen Problemen nicht verwertet werden. Der daraufhin entwickelte in 
vivo Ansatz zeigte jedoch gegensätzliche Befunde zum vorherigen in vitro An-
satz, da Tumore und tumorfreie Regionen der intratracheal behandelten K-
rastm3Tyj Mäuse eine ähnliche Aufnahme der zielgerichteten MSNs und Kontroll-
partikeln zeigten. Im Gegenteil, Kontrollpartikel und zielgerichtete MSNs wurden 
in gleichem Maße von Alveolarmakrophagen aufgenommen, obwohl diese eine 
hohe Expression von CCR2 zeigten .   
Zusammenfassend lässt sich sagen, dass unsere Daten bereits vorhandene Da-
ten zur Überexpression und der wichtigen Rolle des CCR2 Rezeptors in der Ent-
wicklung des Lungenkarzinoms bestätigen. Auch die Möglichkeit einer zielgerich-
teten Therapie gegen diesen Rezeptor wurde noch einmal bekräftigt. Allerdings 
konnten wir einen Funktionsverlust des zielgerichteten Therapieversuchs in vivo 
beobachten, obwohl dieser Ansatz in vitro gute Ergebnisse erzielte. Dies bestä-
tigt zum Einen die wichtige Rolle von Alveolarmakrophagen in der Beseitigung 
von Nanopartikeln, die lokal der Lunge zugeführt werden. Zum Anderen zeigt es 
auf, dass detaillierte in vivo Experimente zur Beurteilung der therapeutischen Ef-
fektivität funktionalisierter Nanopartikeln notwendig sind. 
  
Summary 
  6 
Summary 
Lung cancer has one of the highest mortality rates worldwide and even though 
advancements in treatment schemes have been made over the last years, lung 
cancer stays on top of the list for causes of cancer related deaths with a 5-year 
survival rate of 15,9%. In addition, early diagnosis and thus early treatment for 
lung cancer has not been achieved yet. In the past years treating the cancer mi-
croenvironment and especially tumor-associated macrophages has been a major 
field of discussion. In addition, an emphasis on new targeted therapy strategies 
for cancer treatment has been made. As the idea is to target only tumor cells, 
healthy tissue should be spared and hence side effects of the therapy should be 
reduced. One approach to actively target tumor cells and tumor-associated mac-
rophages is with the help of nanoparticles. These nanometer size particles can 
consist of different materials and can, for example, encapsulate chemotherapeu-
tics to release them at a specific stimulus. In addition, ligands can be attached to 
actively target cells expressing a fitting receptor.  
For this purpose, our collaborators designed mesoporous silica nanoparticles 
(MSNs) in a way that they release their cargo only in an acidic environment. In 
addition, for active targeting these MSNs can be functionalized by adding a tar-
geting ligand binding to receptors highly expressed in lung cancer. Hence the aim 
of this thesis was to validate CCR2-targeted mesoporous silica nanoparticles for 
a targeted therapy approach to lung cancer, as the CCR2 receptor is commonly 
overexpressed on cancer cells and tumor-associated macrophages in lung can-
cer patients.  
For the evaluation of the CCR2-targeted MSNs an in vitro, ex vivo and in vivo 
experimental setup was designed. Firstly, we could confirm the expression of 
CCR2 in human lung cancer samples and tumors of K-rastm3Tyj mice, a well-es-
tablished lung cancer animal model. Secondly, we could show an increased up-
take of CCR2-targeted MSNs in CCR2 expressing MHS cells in comparison to 
the control particles. Thirdly, ex vivo lung slices of K-rastm3Tyj mice were treated 
with MSNs and uptake differences in tumor and tumor free regions was assessed. 
However, experimental difficulties led to the discard of these results. Following, 
an in vivo approach in which K-rastm3Tyj mice were treated with the named parti-
cles by intratracheal administration was conducted. Interestingly, the positive in 
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vitro results could not be observed, as no difference in uptake of CCR2-targeted 
MSNs in tumor and tumor free regions could be noticed and alveolar macro-
phages incorporated CCR2-targeted and control particles to a similar extent yet 
expressing a high amount of CCR2 receptors.  
Taken together, our data confirms recent studies stating the importance of the 
CCR2 receptor in lung cancer development and the possibility of using this re-
ceptor as a target for specific therapy approaches. However, as we show a loss 
of targeting abilities of functionalized MSNs in vivo, out data stress the importance 
of alveolar macrophages in the clearing process of nanoparticles when adminis-
tered locally to the lung. In addition, the lost targeting capacities of the MSNs 
underline the need for careful in vivo studies of functionalized targeted nanopar-
ticles. 
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1 Introduction 
1.1 Lung cancer  
1.1.1 Lung cancer epidemiology and symptoms  
Lung cancer has one of the highest incidence rates of cancers worldwide and is 
the leading cause of cancer-associated deaths in the United States (Ferlay J, 
2012; Siegel, Miller, & Jemal, 2017) with a 5-year survival rate of 15.9% (Chen, 
Fillmore, Hammerman, Kim, & Wong, 2014; Herold, 2017, pp. 400-405). In Ger-
many, it is the leading cause of cancer associated deaths of males (25%), and 
ranked second for females (15%). In 2013, 29.708 males und 15.140 females 
died due to lung cancer in Germany ("Leitlinienprogramm Onkologie, 2017,") 
The leading risk factor associated with lung cancer is smoking, which is respon-
sible for 85% of all lung carcinomas. The cancer risk depends on the amount of 
smoked cigarettes, which is estimated in pack-years (=number of daily consumed 
cigarette packages times number of years the patient is smoking) (Herold, 2017, 
pp. 400-405). 30 pack-years increase the cancer risk tenfold. Further, 
Secondhand smoke (SHS) can also significantly increase the risk of the disease 
by factor 1.3 - 2. In addition, exposure to carcinogenic factors such as asbestos, 
arsenic, ionizing radiation and radon at work or at home increase the risk to de-
velop lung cancer (Herold, 2017, pp. 400-405). Moreover, patients having an un-
derlying lung disease such as COPD, chronic bronchitis, emphysema or pulmo-
nary fibrosis are more likely to develop lung cancer than healthy individuals 
(Collins, Haines, Perkel, & Enck, 2007; Avrum Spira, Halmos, & Powell, 2015; A. 
Spira, Halmos, & Powell, 2016).  
 
1.1.2 Lung cancer diagnosis  
Lung cancer does not cause specific symptoms, leading to a problem in early 
diagnosis. Most of the patients present with non-specific manifestations, such as 
weight loss, fatigue, cough, dyspnea, hemoptysis and chest discomfort (Collins 
et al., 2007; Herold, 2017, pp. 400-405). However, lung cancer can be accompa-
nied by systemic symptoms due to paraneoplastic syndromes, as approximately 
10% of lung cancers produce bioactive substances (Collins et al., 2007; Herold, 
Introduction 
  9 
2017). In addition, another presentation of lung cancer is the Pancost Syndrom, 
defined by a tumor developing in the lung apex and eroding the thoracic wall, 
thus leading to a Horner Syndrome (Miosis, Ptosis and Enopthalmus) as well as 
to swelling of the arm and neuralgic pain (Herold, 2017).  
Lung tumors can first be seen with radiological imaging, such as thoracic x-ray, 
computer tomography (CT) or high resolution computer tomography (HRCT). Fig-
ure 1-1 displays an area with higher density in the right upper lobe of a lung on a 
X-Ray (a) and CT (c) scan, showing a typical result of a lung tumor. In addition, 
endobronchial ultrasonography can detect lung lesion (Collins et al., 2007; 
Herold, 2017; Avrum Spira et al., 2015). However, for specific diagnosis biopsies 
are needed, which can be taken via bronchoscopy while identifying lesions with 
autofluorescence (A. Spira et al., 2016). Other options include endoscopic ultra-
sonography-guided needle aspiration or video assisted thoracoscopy (Herold, 
2017; Avrum Spira et al., 2015). For assessing metastasis of lung cancer, sonog-
raphy, MRI, CT or PET-CT scans can be an option (Collins et al., 2007; Herold, 
2017). 
 
 
Figure 1-1 Lung tumor in X-Ray and CT scans 
Lung tumors (area with the higher density) in the right upper lobe seen on an X-ray (a) and CT 
scan (c). (Figure adopted and modified from Arastéh, 2013). 
 
As described above, early stage lung cancer causes nearly no symptoms, thus 
lung cancer screening has been a focus in lung cancer research in recent years. 
Nonetheless, there is an open debate whether screening for lung cancer with the 
current diagnostic modalities in the healthy population is beneficial, as only one 
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trial in the United States with a subject group of 55 to 77 years old smokers highly 
at risk for lung cancer and screening with low-dose CT showed a survival benefit 
in the screened group (Aberle DR, 2011). Other European studies with lower risk-
populations revealed no difference in lung cancer mortality between the screen-
ing and non-screening group (Herold, 2017; A. Spira et al., 2016). However, 
these conclusions may be re-evaluated when better risk scores, diagnostic path-
ways and agents such as diagnostic biomarkers are developed (Osmani, Askin, 
Gabrielson, & Li, 2017; A. Spira et al., 2016).  
 
1.1.3 Lung cancer classification 
Histologically lung cancer can be classified into small cell lung cancer (SCLC), 
defined by small cells with a small amount of cytoplasm as seen in Figure 1-2, 
and non-small cell lung cancer (NSCLC) with the latter being the most common 
form (85%) (Chen et al., 2014). Non-small cell lung cancer can then be subdi-
vided into Squamous cell carcinoma (Figure 1-2), Adenocarcinoma (Figure 1-2), 
Large cell carcinoma, Adenosquamos carcinoma, Sarcomatoid carcinoma, Car-
cinoid tumor and tumors of bronchial glands (Travis William D., 2015).  
 
 
Figure 1-2 Histological classification of lung tumors 
Selection of histological features of Small cell lung cancer, Squamous cell carcinoma and Ade-
nocarcinoma of the lung. (Figure adopted and modified from Travis William D., 2015). 
 
In addition, lung cancer, as all malignant tumors, can be classified by the TNM 
Classification (T-Tumor size and spread, N – number of tumor infected lymph 
nodes, M – Presence and number of metastatic lesions), which is also used for 
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grouping different lung tumors into a disease stage as presented in Figure 1-3 
(Travis William D., 2015).  
 
Figure 1-3: TNM Classification of lung tumors and Stage Grouping 
Malignant lung tumors can be classified by size (T1 - 4), number of tumor infected lymph nodes 
(N1 – 3) and whether or not distant metastasis occurred (M0 / M1). (Figure adopted from Travis 
William D., 2015). 
 
SCLC (Figure 1-2), whose name is originated from the small cells with bare cyto-
plasm it consists of (Travis William D., 2015), has the worst prognosis of all lung 
cancer subtypes and is normally located in the central lung. As it has a very high 
tumor doubling rate, 80% of the cases are metastasized when diagnosed (Herold, 
2017; Travis William D., 2015). Thus, SCLC is often categorized in disease 
stages - very limited disease (small tumor size and no metastasis), limited dis-
ease (greater tumor size and lymph node metastasis) and extensive disease (at 
least one metastatic lesion) (Collins et al., 2007; Herold, 2017).  
The prognosis of NSCLC depends on the tumor subtype, tumor stage at time of 
diagnosis and the health status of the patient (Herold, 2017). Adenocarcinomas 
(Figure 1-2) and squamous cell carcinomas (Figure 1-2) have the highest 
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prevalence of all NSCLC subtypes. Adenocarcinomas, which are the most com-
mon malignant lung tumors among non-smokers, consist of a glandular structure 
and are more likely to develop in the periphery as seen in Figure 1-4 (Chen et al., 
2014; Herold, 2017). They express a wide range of biomarkers, which can be 
detected via immunohistochemistry (IHC) such as Napsin A and thyroid transcrip-
tion factor 1 (TTF1) (Chen et al., 2014; Osmani et al., 2017; Travis William D., 
2015).  
 
 
Figure 1-4 Differences between NSCLC subtypes 
Squamous Cell Carcinoma (SCC) and Adenocellcarcinoma (ADC) develop in different areas of 
the lung and tumor growth is driven and modeled by different driver mutations. SCC arises from 
the pseudostratified columnar epithelium of proximal airways whereas ADC evolves in the distal 
lung. The tumor entities can be histologically differentiated by markers such as p63 and TTF1. 
(Figure adopted  from Chen et al., 2014).   
 
Squamous cell carcinomas (Figure 1-2), which are greatly associated with smok-
ing, show a squamous differentiation and arise in the proximal regions of the air 
conducting pathways as presented in Figure 1-4 (Chen et al., 2014; Herold, 
2017). They mostly express P40 and P63, cytokeratine 5 and 6 (CK5/6), as well 
as carcinoembryonic antigen (CEA). (Osmani et al., 2017; Travis William D., 
2015). However, as IHC staining of biopsies is time and tissue consuming, triple 
markers combining staining for TFF1, Napsin A and P40 have been developed 
to distinguish the two main NSCLC subtypes. They show a higher sensitivity and 
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specificity than each marker alone and can be used with less biopsy material 
(Osmani et al., 2017). Furthermore, Adenosquamos carcinoma, Large cell carci-
noma, Sarcomatoid carcinoma and also some carcinoid tumors are defined as 
NSCLC. However, because their prevalence is comparably low, they are not 
mentioned in greater detail here.  
 
1.2 Lung cancer development 
1.2.1 Basic principles of oncogenesis 
In the developmental process of a tumor, cancerous and surrounding cells ac-
quire distinct features facilitating tumor growth and metastasis. Through gaining 
genomic instability and mutations, tumor cells acquire the ability to sustain unlim-
ited proliferation, to evade proliferation suppression, to resist cell death, to permit 
unlimited replicative cycles, to generate angiogenesis and to stimulate metasta-
sis. In addition, they are able to deregulate their energetic system, to avoid de-
struction through immune cells and instead promote pro-tumorous inflammatory 
processes (Hanahan & Weinberg, 2000, 2011). However, not only cancer cells 
are responsible for the expansion of tumors but also stromal cells, such as fibro-
blasts, endothelial cells and immune cells, altogether being called the tumor mi-
croenvironment. As these cells are attracted and activated by the tumor, they turn 
from tumor suppressing to tumor promoting cell types, helping the tumor to grow, 
form pre-metastatic niches, invade surrounding tissue and suppress anti-tumor 
responses (Hanahan & Coussens, 2012; Hanahan & Weinberg, 2011; Quail & 
Joyce, 2013).  
In the presence of cancer cells, vascular endothelial cells, for example, are acti-
vated through an “angiogenic switch” allowing them to form new vessels within 
the tumor and hence promote angiogenesis (Hanahan & Coussens, 2012). In 
addition, cancer associated fibroblasts are activated by growth factors and cyto-
kines and transform into pro-tumorous cells and, for example, secrete extra cel-
lular matrix (ECM) components or perform aerobic glycolysis. They thus provide 
the tumor with energy in form of lactate and pyruvate (Hanahan & Coussens, 
2012; Quail & Joyce, 2013). Another important cell group in the tumor microenvi-
ronment are immune cells: Neutrophils, lymphocytes, monocytes, mast cells, 
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natural killer cells and macrophages can all be changed into pro-tumorigenic phe-
notypes by either being attracted by the tumor or by already being resident in the 
tumorous tissue site (Hanahan & Weinberg, 2011). They perform various tasks 
such as supplying growth factors (e.g. Epidermal growth factor (EGF), transform-
ing growth factor beta (TGF-ß), fibroblast growth factor (FGF)), cytokines, inter-
leukins, chemokines and histamine. In addition, they produce various proteolytic 
enzymes (e.g. metallo- and serine-proteinases), which can modify the extracel-
lular matrix (ECM) and hence help the cancer cells to mobilize and form metas-
tasis (Hanahan & Coussens, 2012). Further, myeloid-derived suppressor cells 
and regulatory T-cells can suppress anti-tumor responses for example by inter-
rupting antigen presentation (Quail & Joyce, 2013).  
Another distinct pro-tumorous cell type in the tumor microenvironment are tumor-
associated macrophages (TAMs). TAMs influence tumor growth and progression 
as they, for example, promote angiogenesis by secreting high amounts of pro-
angiogenic factors such as Vascular endothelial growth factor (VEGF) and growth 
factors such as EGF (Hanahan & Coussens, 2012; Noy & Pollard, 2014; Ostuni, 
Kratochvill, Murray, & Natoli, 2015). Another function is the promotion of cancer 
cell invasion and migration. TAMs modulate the ECM by production of proteases 
including matrix metalloproteinases (MMPs), which degrade the ECM and base-
ment membranes and allow cancer cells to migrate to different sites (Qian & 
Pollard, 2010).  
However, an additional mechanism that helps the tumor cells to escape the im-
mune system works different than the pathways outlined above. In this case, it is 
not the tumor microenvironment that acts pro-tumorigenic, but cancer cells find a 
way to escape anti-tumor T-cell responses. They express a high amount of pro-
grammed death ligand 1 (PDL-1), a ligand that binds to the programmed cell 
death protein 1 (PD-1) on T-cells, inhibiting anti-tumor T-cell responses (Pardoll, 
2012). Inhibiting this pathway as a therapy strategy has been investigated thor-
oughly in recent years (Langer, 2015). 
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1.2.2 Lung cancer driver mutations and lung cancer tumor microenviron-
ment. 
As mentioned above there are several different types of lung cancer and thus 
there are various driver mutations enabling tumor cells to perform the above men-
tioned features, thus promoting lung cancer development. Small cell lung cancer 
development for example is induced through mutations of p53, inactivation of the 
retinoblastoma gene or amplification of MYC (Travis William D., 2015).  
However, NSCLC is driven by different genetic mutations. Very common genetic 
alterations in adenocarcinomas are, for example, TP53 mutations, K-ras muta-
tions as well as epidermal growth factor receptor (EGFR) mutations and amplifi-
cation (Blakely et al., 2017; The Cancer Genome Atlas Research, 2014). In ad-
dition, BRAF, MET, PIK3CA and others can be mutated (Chen et al., 2014; 
Hirsch, Suda, Wiens, & Bunn, 2016; The Cancer Genome Atlas Research, 2014). 
Furthermore, there is a high prevalence of co-occurrence of EGFR driver muta-
tions with other genetic alterations for example mutations in MET, PIK3CA, MYC 
and CDK6. This co-occurrence of different genetic alterations might influence 
lung cancer therapy, especially targeted therapy approaches (Blakely et al., 
2017).  
Driver mutations in adenocarcinoma differ from those in squamous cell carci-
noma, as genetic alterations in Lkb1, DDR2, FGFR1, FGFR2 and FGFR3 play a 
more important role. In addition, mutations in the PIK3 pathway as well as p53 
mutations and others contribute to squamous cell carcinoma development 
(Figure 1-4) (Chen et al., 2014; Hirsch, Scagliotti, et al., 2016; Travis William D., 
2015). Besides cancer cell heterogeneity in lung cancer, several publications 
suggest a diverse microenvironment in different NSCLC subsets. Pro-tumor-
igenic stromal cells, immune cells and endothelial cells can also be detected in 
the tumor microenvironment of lung cancer and fulfill functions as described 
above and shown in Figure 1-5 (Chen et al., 2014; Conway et al., 2016; Remark 
et al., 2015). 
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Figure 1-5 Lung cancer microenvironment 
The lung cancer microenvironment consists of different cell types such as T-cells, neutrophils, 
fibroblasts and macrophages all helping the tumor grow and metastasis. Tumor-associated mac-
rophages, for example, secret growth factors and ECM components. (Figure adopted from Chen 
et al., 2014) 
 
B-cells, Natural killer cells, tumor-associated macrophages, neutrophils and oth-
ers also interact with lung cancer cells through chemokines and interleukins and 
promote lung cancer development (Remark et al., 2015). Further, the PDL-1 and 
PD-1 Interaction described above and displayed in Figure 1-5 plays an important 
role in lung cancer and has fostered many new therapeutic strategies (Garon et 
al., 2015; Langer, 2015).  
 
1.2.3 Tumor-associated macrophages in lung cancer  
As mentioned above and shown in Figure 1-5, tumor-associated macrophages 
play an important role in cancer development. The presence of TAMs in the tumor 
microenvironment has been strongly associated with poor prognosis in several 
malignancies such as thyroid, breast and hepatic as well as lung cancer, espe-
cially NSCLC (Conway et al., 2016; Grivennikov, Greten, & Karin, 2010; Ostuni 
et al., 2015; Qian & Pollard, 2010). In addition, numerous studies have shown 
infiltration of TAMs in metastatic lesions in the lung, suggesting that they play a 
crucial role in the evolution of the pre-metastatic niche (Noy & Pollard, 2014). The 
effect of TAMs on lung cancer development is stressed by multiple studies, which 
show that depletion of macrophages in lung tumor models is followed by a reduc-
tion in tumor growth and metastasis rate (Ostuni et al., 2015; Qian & Pollard, 
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2010). However, contrary reports suggest that this depends on the localization of 
TAMs. They propose that TAMs localized in tumor islets and thus in between the 
tumor cells are correlated with higher survival rates in NSCLC patients and that 
TAMs localized around the tumor in the tumor stromal/microenvironment corre-
late with a poor prognosis (Conway et al., 2016; Remark et al., 2015). 
TAMs typically arrive from circulating blood monocytes and are attracted to the 
tumor site by the chemokine CCL2, which binds to its receptor CCR2 on the mac-
rophage surface (Ostuni et al., 2015). Once TAMs reach the tumor site, several 
growth factors such as colony stimulating factor (CSF1), granulocyte-macro-
phage colony stimulating factor (GM-CSF) and IL4 activate intracellular pathways 
programming them into a pro-tumorigenic phenotype (Noy & Pollard, 2014). In 
addition, VEGF, the chemokines CCL18 and CCL9 and interleukines IL3 and 
IL10 play a role in this process (Noy & Pollard, 2014; Ostuni et al., 2015; Qian & 
Pollard, 2010).  
The CCL2-CCR2 axis plays an important role in the recruitment and function of 
TAMs in lung cancer and lung metastasis: the presence of CCL2 and CCR2 cor-
relates with poor prognosis in lung cancer models and was detected in metastatic 
lesions in the lung of several cancer types (Ostuni et al., 2015; Qian & Pollard, 
2010). Further, a preclinical approach of targeting the CCL2-CCR2 axis by anti-
bodies against the chemokine showed a positive therapeutic effect as metastatic 
lesions in the lung decreased (Ostuni et al., 2015). 
 
1.3 Lung cancer treatment 
In general, lung cancer can be treated by three modalities – surgery, chemother-
apy and radiotherapy, depending on the type of lung cancer, the stage at time of 
diagnosis and the individual receptor expression. Early stage (limited disease) 
SCLC can be treated by primary resection combined with radio- and chemother-
apy. In this case, cisplatin and etoposide are the standard chemotherapeutics. 
However, when SCLC is, as it is mostly the case, detected in a late disease stage, 
primary palliative chemotherapy is the favored treatment option (Herold, 2017; 
Avrum Spira et al., 2015).  
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In the case of NSCLC, treatment options depend on the disease stage as well as 
on the individual receptor expression and molecular pattern of the tumor. The first 
line therapy of early stage NSCLC patients (stage I, II, IIIA) is the surgical resec-
tion of the tumor by lobectomy. Depending on the patient’s comorbidity and age, 
a sublobar resection or a stereotactic ablative radiotherapy can also be chosen. 
In addition, patients may benefit from a perioperative chemotherapy or from 
chemotherapy in combination with thoracic radiotherapy (Herold, 2017; Avrum 
Spira et al., 2015). Adding Bevacizumab (anti-vascular endothelial growth factor 
antibody), however, showed no benefit in early stage NSCLC treatment (Hirsch, 
Scagliotti, et al., 2016; A. Spira et al., 2016).  
Patients with advanced stage NSCLC may be eligible for targeted molecular ther-
apies and therefore need to be tested before initiating treatment. If they do not 
meet the requirements for the approved molecular therapies, the first line therapy 
is a platinum-based doublet chemotherapy, which can be expanded with Bevaci-
zumab if the tumor is not a squamous cell carcinoma (Herold, 2017; Hirsch, 
Scagliotti, et al., 2016). Nonetheless, if the NSCLC has a certain molecular pro-
file, patients might be qualified for targeted therapy approaches. Several targeted 
therapies against oncogenic proteins in NSCLC have been approved such as 
against EGFR amplifications (e.g. Gefitinib, Erlotinib, Afatinib, Osimertinib), ALK- 
(e.g. Crizotinib, Alectinib) or ROS1- inhibitors (e.g. Crizotinib) and others are in 
phase two or three clinical trials (Herold, 2017; Hirsch, Scagliotti, et al., 2016; A. 
Spira et al., 2016).  
As the tumor microenvironment plays an important role in NSCLC development, 
several treatment approaches of inhibiting TAMs and other immune cells have 
been developed. Novel therapies with anti-PD-1 antibodies Nivolumab or Pem-
brolizumab have been approved for metastatic NSCLC tumors after failure of the 
platinum based chemotherapy and others currently are in phase two or three clin-
ical studies (Garon et al., 2015; Herold, 2017; A. Spira et al., 2016). Durvalumab, 
a PDL-1 Inhibitor, has recently shown positive results in a phase two clinical study 
with pretreated patients suffering from advanced non-small cell lung cancer 
(Garassino et al., 2018).  
 
Introduction 
  19 
1.4 Nanoparticle-based drug delivery 
1.4.1 Concept and advantages of nanotherapy 
Nanoparticle-mediated drug delivery is an evolving therapeutic strategy in the 
field of cancer treatment. As conventional chemotherapeutics fail, challenges 
such as drug instability, short circulation time, unspecific targeting and increased 
side effects are of greater concern. Thus nanoparticle drug delivery systems, 
which are a broad range of therapeutic carrier systems, have been developed to 
address these problems (Torchilin, 2014).  
Nanoparticles are nanometer sized (1-200 nm) particles, consisting of different 
materials, which can be loaded with or attached to a drug. As seen in Figure 1-6, 
there are particles containing a structure of organic material, such as proteins, 
carbon or carbohydrates and lipids and there are particles consisting of inorganic 
material such as metals or silica. In addition to their structure, their surface can 
be modified by adding targeting ligands, imaging or cell penetration agents (Tor-
chilin, 2014; Wicki et al, 2014; Lammers et al, 2011). There are diverse types of 
nanoparticles including liposomes, micelles, metal nanoparticles, dendrimers, 
polymeric and mesoporous silica nanoparticles (Figure 1-6). Besides their use in 
cancer, nanoparticles are also used for imaging and for therapeutic approaches 
in other diseases such as cardiovascular disease and infections (Torchilin, 2014). 
Common cancer targeting nanoparticle therapy approaches are “lipid based 
nanocarriers”, “polymer based nanocarriers”, “inorganic nanoparticles”, “viral na-
noparticles” and “drug conjugates” (Wicki, Witzigmann, Balasubramanian, & 
Huwyler, 2015). These nanoparticles try to address the problems mentioned for 
common cancer therapeutics: They prolong circulation times, as they protect their 
cargo from enzymatic or non-enzymatic degradation and make therapeutics sol-
uble. This protects them against renal clearance and therefore expands the bio-
availability of the drugs (Lammers, Kiessling, Hennink, & Storm, 2012; Torchilin, 
2014; Wicki et al., 2015). 
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Figure 1-6 Nanoparticle drug delivery systems 
Common nanoparticles used for drug delivery in cancer therapy. (Figure adopted from Wicki et 
al., 2015) 
 
Further, nanoparticles can increase passive and active targeting of the drug. As 
tumors promote angiogenesis and enhance permeability of blood vessels, nano-
particles are transported to the tumor site to a greater extend than to other tissues 
and can leak to the tumor tissue through the permeable blood vessel structure. 
This is called the enhanced permeability and retention effect (EPR effect) and is 
responsible for an enhanced passive tumor targeting (Matsumura & Maeda, 
1986). The first generation of nanomedicines for cancer primarily relied on pas-
sive targeting, using the EPR effect. However, this effect has some limits, as in-
terstitial fluid pressure and heterogeneity of the tumor stromal can decrease the 
outcome and the particles can also be deposited in other organs with high blood 
supply (Lammers et al., 2012; Torchilin, 2014; Wicki et al., 2015). Thus, more 
potent targeting approaches have been developed. By conjugating nanoparticles 
with specific ligands, active targeting (Figure 1-7) of the tumor and/or surrounding 
cells can be achieved. By attaching a ligand or an antibody to the nanoparticle 
surface, which is directed to an overexpressed receptor on a cell (e.g. EGFR, 
HER2), the specific attachment of the nanoparticle to a cell type is possible and 
thus treatment is specific to this cell type (Lammers et al., 2012; Torchilin, 2014; 
Wicki et al., 2015). 
In addition to the advances made in active targeting of nanotherapy, there has 
been improvement in the development of stimuli sensitive nanocarriers, as they 
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can be engineered to release their cargo upon specific stimuli such as acidic pH, 
hyperthermia, catalytic enzymes and hypoxia (Figure 1-7). Thus, nanoparticles 
can be developed that are only effective in certain tissues or areas, which again 
increases the targeting and reduces side effects (Lammers et al., 2012; Torchilin, 
2014; Wicki et al., 2015). All of these functions can be combined, resulting, for 
example, in particles with a prolonged circulation time and targeting functions or 
particles that deliver multiple drugs at the same time and are stimuli-sensitive 
(Torchilin, 2014).  
 
 
Figure 1-7 Targeting mechanisms of nanoparticle drug delivery systems 
Nanoparticles can reach a target at the tumor site through different mechanisms. Passive target-
ing is achieved through a higher blood supply in the tumor and a higher permeability of the ves-
sels. Active targeting, however, can be achieved by adding ligands to the nanoparticles and thus 
targeting structures on different tumor cell types such as cancer cells or endothelial cells. In ad-
dition, particles can be engineered to release their cargo in the presence of certain stimuli. (Figure 
adopted and modified from Lammers et al., 2012) 
 
1.4.2 Nanotherapy in lung cancer 
Among the groups of nanoparticles mentioned above, conjugated drugs have 
been the most successful systems in lung cancer therapy to date. They are drugs 
conjugated to targeting antibodies or ligands for prolonged circulation time and 
some have already been approved for clinical use. Among them is Abraxane, an 
albumin bound nanoparticle carrying Paclitaxel, which is also in use for NSCLC 
therapy (Bolukbas & Meiners, 2015; Wicki et al., 2015). Another nanotherapy for 
NSCLC, which was already approved in 2015, is a Paclitaxel loaded micelle 
(Genexol-PM). Besides these two approved drugs, there are several clinical trials 
for nanotherapies in lung cancer using for example liposomes, PEG-conjugation, 
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micelles and gold-silica nanoparticles (Bolukbas & Meiners, 2015; Landesman-
Milo, Ramishetti, & Peer, 2015). Especially lipid based carrier systems have been 
developed, as they can encapsulate the drugs easily, are biocompatible and can 
be modified on their surfaces (Landesman-Milo et al., 2015). However, their low 
bio-stability and rapid renal clearance can be a problem (Yang & Yu, 2016).   
So far lung cancer therapeutics have been delivered through intravenous or oral 
application. Another approach can be inhalation therapies as the local admin-
istration of the drug can potentially reduce side effects, decrease biodegradation 
and enhance cell-specific targeting. However, so far there are predominantly pre-
clinical studies with antibody and cytotoxic drug delivery via inhalation, as con-
cerns about occupational exposure, systemic effects and total lung toxicity have 
been raised (Abdelaziz et al., 2018; Kuzmov & Minko, 2015). In addition, local 
pulmonary clearance and lung specific side effects, such as high lung toxicity, 
impede inhalative approaches from entering clinical practice. Nonetheless, there 
is still a lack of clinical studies with inhalable nanoparticle formulations. As of yet 
only, a few lipid based approaches have been tested (Abdelaziz et al., 2018).  
 
1.4.3 Mesoporous silica nanoparticles for nanotherapy 
One of the evolving nanoparticles for targeted drug delivery and imaging ap-
proaches are mesoporous silica nanoparticles (MSNs). They consist of a silica 
core structure with various pores and can be formed in diverse morphologies 
such as spheres, hemi-spheres or dendritic structures. Further, their size and 
pore size can be altered according to the desired function (Yang & Yu, 2016).  
A unique feature of MSNs is their porous structure, which can be sealed with 
different agents allowing a controlled release mechanism as seen in Figure 1-8 
(Argyo, Weiss, Bräuchle, & Bein, 2014; Yang & Yu, 2016). In addition, MSNs are 
frequently used because of their ability to load a high amount of drugs, their high 
bio-stability and their relatively low cytotoxicity (Yang & Yu, 2016). Moreover, the 
surface of MSN can be easily modified: Ligands can be attached for specific tar-
geting, gatekeepers for the pores can be introduced to allow a stimuli-sensitive 
release and coatings such as lipid layers, charged groups or polymers can be 
added for a higher bio-stability (Argyo et al., 2014). 
Introduction 
  23 
 
 
Figure 1-8 Different possibilities of modifying Mesoporous Silica Nanopaticles  
The surface of MSNs can be modified through adding different ligands, gatekeepers, markers, 
spacers and triggers and thus targeting and cargo release mechanisms can be altered. In addi-
tion, different cargos can be packed inside the particle. (Figure adopted and modified from Argyo 
et al., 2014) 
 
However, there are no clinical trials for NSCLC therapy approaches with MSNs 
and only a few preclinical studies have been published so far. In 2015, one phase 
one clinical trial has been started with gold-silica nanoshells and only a few pre-
clinical studies with pure MSNs directed against EGFR overexpressing and lute-
inizing hormone releasing hormone receptor (LHRHR) overexpressing cells were 
initiated (Bolukbas & Meiners, 2015). Thus, there is still potential for developing 
MSN based therapy approaches for lung cancer. 
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2 Aim of the study 
Lung cancer has one of the highest mortality rates of all cancers world-wide and 
as common chemotherapeutics fail to provide a promising effect, recent research 
has focused on new targeted therapeutic agents, which have shown to enhance 
cell specific toxicity while sparing healthy tissue. In addition, the focus has not 
only been on treating cancer cells but also on treating the lung cancer microen-
vironment, consisting of stromal and immune cells including tumor-associated 
macrophages (TAMs), that play an important role in the tumor initiation and de-
velopment. In lung cancer, the chemokine receptor 2 (CCR2) is commonly over-
expressed specifically on TAMs and cancer cells, thus targeting this receptor 
could be a valid strategy for a specific targeting therapy approach. So far, several 
targeted therapeutic agents for lung cancer against oncogenic proteins (e.g. Er-
lotinib or Afatinib) as well as against immune cell interactions (e.g. Pembroli-
zumab) have been approved. However, other options of targeting therapy ap-
proaches are nanoparticle-based carrier systems, among those are mesoporous 
silica nanoparticles (MSNs), as these can be modified to actively target specific 
cells. Accordingly, our idea was to functionalize a CCR2-targeting ligand on the 
surface of the MSNs to incorporate cell specific targeting for lung cancer treat-
ment.  
Therefore, the purpose of this study was to validate CCR2-targeted MSNs for 
lung cancer therapy and the aims were to test, 
• whether CCR2-targeted MSNs are specifically taken up by CCR2 ex-
pressing cells in vitro. 
• whether CCR2-targeted MSNs are preferentially taken up by CCR2 
positive tumor cells and tumor-associated macrophages in a mouse 
model of lung cancer ex vivo and in vivo. 
To this end, a CCR2 expressing cell line was used and CCR2-targeted MSNs 
were tested for their specific cellular uptake in vitro using confocal microscopy 
and flow cytometry analysis. 3D lung tissue cultures of wild type and K-ras mutant 
mice were used as an ex vivo model to observe specific uptake of the particles 
in tumor regions. In addition, an in vivo approach was conducted where the par-
ticles were locally applied to the lungs of K-ras mutant mice, to evaluate the bio-
distribution and specific tumor-targeting of the CCR2-targeted MSNs.  
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3 Materials and Methods 
3.1 Materials 
3.1.1 Antibodies  
Table 1: Primary antibodies 
Antigen Host Application and Dilution Supplier 
CCR2 Rabbit IHC: 1:1000 
WB: 1:1000 
IF: 1:500 
Novusbio 
(NB110-55674) 
CD68 Mouse IF: 1:50 Novusbio 
(NBP1-74570) 
β-Actin Mouse WB: 1:50000 Cell Signaling 
(13E5) 
 
Table 2: Secondary antibodies 
Antibody Host Application and         
Dilution 
Supplier 
Alexa Flour 488 anti-rab-
bit 
Goat IF: 1:750 Life technologies 
Alex Flour 568 anti-rabbit Goat IF: 1:750 Life technologies 
Alexa Flour 488 anti-
mouse 
Goat IF: 1:750 Life technologies 
Anti-Rabbit HRP-linked Goat WB: 1:40000 Cell Signaling 
Rabbit-on-Rodent               
AP-Polymer 
 IHC Zytomed 
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3.1.2 Buffers and Solutions  
Table 3: Buffers for immunohistochemistry 
Buffers Reagents Concentrations 
Citrate buffer, pH 6 Citric acid monohydrate 
Sodium citrate tribasic 
1.8 mM 
8.2 mM 
TBS Tris 
NaCl 
24.2 g (0.242%) 
80 g (0.8%) 
TBST TBS 
Tween-20 
1 x 
0.0002% 
 
Table 4: Buffers for immunoflorescence 
Buffer Reagents Concentrations 
PBS NaCl 
KCl 
Na2HPO4 
KH2PO4 
137 mM 
2.7 mM 
10 mM 
2 mM 
 
Table 5: Buffers for flow cytometry 
Buffer Reagents Concentrations 
FACS-Buffer PBS 
FBS 
1 x 
0.02% 
FACS-Blocking buffer PBS 
BSA 
1 x 
0.5% 
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Table 6: Buffers for DNA extraction 
Buffer Reagents Concentrations 
PBND KCl 
Tris-HCL pH 8.3 
MgCl2 
Gelatin 
Nonidet P40 
Tween 
H2O 
50 mM 
10 mM 
2.5 mM 
0.01% 
0.45% 
0.45% 
 
Table 7: Buffers for protein extraction 
Buffer Reagents Concentrations 
RIPA Tris/HCL, ph7,5 
NaCl 
NP40 
Sodiumdeoxycholate 
SDS 
Complete© Protease Inhibitor 
50 mM 
150 mM 
1% 
0.5% 
0.1% 
1 x 
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Table 8: Buffers for Western Blot 
Buffer Reagents Concentrations 
Laemmli Buffer Tris/HCL, pH 6,8 
Glyercol 
SDS 
DTT 
Bromophenol blue 
300 mM 
60% 
6% 
5% 
0.01% 
SDS-Page resolving gel (10%) Tris/HCL, pH 8,8 
SDA 
Acrylamide 30% 
APS 
TEMED 
375 mM 
0.06% 
10% 
0.125% 
15% 
SDS-Page stacking gel (3,6%) Tris/HCL, pH 6,8 
SDS 
Acrylamide 30% 
APS 
TEMED 
125 mM 
0.1% 
3.6% 
0.125% 
0.3% 
SDS-Page Running buffer Tris 
Glycine 
SDS 
25 mM 
0.192 M 
0.1% 
10x SDS-Page transfer buffer Tris 
Glycine 
Methanol 
25 mM 
0.192 M 
10% 
PBST PBS 
Tween-20 
1 x 
1% 
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3.1.3 Oligonucleotides 
Table 9: Primers for genotyping  
Primer Sequence 
K-ras wildtype primer 5’-TGCACAGCTTAGTGAGACCC-3’ 
K-ras common primer 5’-GACTGCTCTCTTTCACCTCC-3’ 
K-ras mutant primer 5’-GGAGCAAAGCTGCTATTGGC-3’ 
 
3.1.4 Peptides 
Table 10: Ligands for MSNs 
Name Amino Acid Sequence Supplier 
ECL1 (C) CKLFTGL GenScript 
Scrambled AS sequence CTLLGFK GenScript 
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3.1.5 Cell culture  
Table 11: Cell lines and cell culture medium  
Cell Line/Tissue Culturing Me-
dia 
Supplier  Supplements 
A549 DMEM Life technologies 10% FCS 
1% Penicillin /        
Streptomycin 
MHS RPMI Life technologies 10%FCS 
1% Penicillin /        
Streptomycin 
1 mM Sodium-Py-
ruvate 
10 mM HEPES 
50 µM 2-ME 
3D-lung tissue 
cultures 
DMEM/F12 Life technologies 10% FCS 
1% Penicillin /        
Streptomycin  
1% Amphotericin B 
 
3.1.6 Kits 
Table 12: Kits for different applications 
KIT Application Supplier 
BCA Kit BCA Thermo Scientific 
Immunohistochemistry Kit 
(Vulcan fast red) 
IHC Zytomed 
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3.1.7 Human tissue 
Human tissue was kindly provided by the Asklepios Biobank for Lung Diseases, 
Gauting (project no. 333-10). Tumorous and tumor-free lung tissue from surgi-
cally treated lung cancer patients was used. All experiments with human tissue 
were approved by the Ethics Committee of the Ludwig-Maximilians-University 
Munich, Germany (LMU, project no. 455-12).  
 
3.1.8 Chemicals 
Chemicals were obtained from AppliChem, Sigma-Aldrich, Carl Roth, Roche and 
Thermo Fisher Scientific. 
 
3.1.9 Consumables 
Plastic ware and consumables were obtained from TPP, Greiner bio-one and 
Thermo Fisher Scientific.  
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3.2 Methods 
3.2.1 Synthesis and characterization of nanoparticles 
3.2.1.1 Synthesis of mesoporous silica nanopartilces (MSNs) 
Stefan Datz (Chemistry Department LMU, Group: Prof. Thomas Bein) synthe-
sized the mesoporous silica nanoparticles at the chemistry department of the 
Ludwig-Maximilians University (Cauda, Schlossbauer, Kecht, Zurner, & Bein, 
2009; Schlossbauer, Kecht, & Bein, 2009; Sabine H. van Rijt et al., 2015). The 
mesoporous silica nanoparticles were sealed with avidin and a pH-responsive 
linker. In addition, a ligand was attached for receptor-mediated uptake. For the 
CCR2-targeted MSNs, a CCR2-antagonist (ECL1 (C)) synthesized out of seven 
amino acids (Sequence: CKLFTGL) was used for the attached ligand (Auvynet 
et al., 2016). The antagonist was developed by Combadiere et al. (Patent Appli-
cation US 2015/0011477 A1) and ordered through GenScript. The scrambled 
control particle was produced by attaching a peptide to the particles, which con-
sists of the same amino acids as the antagonist but bound in a different order 
(Sequence: CTLLGFK).  
 
3.2.1.2 Dynamic light scattering and release experiment 
Dynamic light scattering (DLS) measurements as well as the in vitro flourescine 
release experiments were kindly performed by Stefan Datz (Bein Lab, Physical 
Chemistry, LMU). 
 
3.2.2 Cell culture 
3.2.2.1 Culturing of mammalian cells 
For this thesis A549 and MHS cells were used. The cell lines were cultured in the 
appropriate media containing different nutritional factors and antibiotics (Table 
11) and incubated at 37 °C with 5% CO2. Medium exchange with pre-warmed 
medium was performed 2-3 times a week according to the need of the cell line. 
When the cells reached around 80-90% confluency, they were sub-cultured in 
different ratios (1:10 – 1:2) depending on the growth rate and the subsequent 
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procedures. For detachment the cells were washed with PBS and a Trypsin-
EDTA (0.25%) solution was added. Media with 10% fetal calf serum was added 
to stop the activity of Trypsin and the cells were divided and sub-cultured in new 
flasks. Cell lines were cultured until they reached passage 25. 
 
3.2.2.2 Treatment of alveolar macrophages with MSNs 
CCR2-specific uptake of MSNs was first assessed using murine alveolar macro-
phages (MHS cells) in vitro. For treatment with different types of MSNs, the cells 
were seeded into different sized wells depending on the subsequent experiments. 
For immunofluorescence staining of the cells, cover slips were placed in a 12-
well plate and 250 000 and 500 000 cells per well were seeded on top. For de-
termining the MSNs uptake with flow cytometry 500 000 cells per well were put 
in 6-well plates.  
Before seeding, the cells were washed, detached as described above and 
counted using a Neubauer chamber. After seeding, the cells were left in the in-
cubator overnight. The next day, MSNs covalently labeled either with Atto 633 or 
Atto 488 fluorophores were added at a concentration of 50 µg in 1 mL cell culture 
media supplemented with 10% FCS and 1% penicillin/streptomycin and the cells 
were placed for an hour in the incubator for MSN uptake. Afterwards, before con-
tinuing with the different procedures, the treated cells were washed three times 
with ice-cold PBS, and one time with ice-cold NaCl solution (0.15 M, pH 3.0) and 
again three times with ice-cold PBS to completely wash off particles sticking to 
the cover slips or the cell membrane.  
 
3.2.2.3 Flow cytometry analysis 
For assessing the uptake of MSNs with flow cytometry, cells were treated with 
the particles as described above. In this case, the particles were labeled cova-
lently with the Atto 488 fluorophore and the uptake was measured by comparing 
the median fluorescent intensity of the cells treated with different MSNs. After 
washing, the cells were detached from the wells with cell scrapers and dissolved 
in FACS buffer containing 2% FCS. Flow cytometry analysis was performed using 
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the LSR II (BD Biosciences) and the fluorescent intensity was assessed. 10 000 
cells were counted for each condition. 
 
3.2.2.4 Immunofluorescence staining 
As another method for measuring the specific uptake of MSNs, immunofluores-
cence staining was used. For this procedure, MHS cells were incubated with 
MSNs labeled with Atto 633 for one hour. The cells were seeded on cover slips, 
treated and washed afterwards as described above. For fixing, they were incu-
bated in 70% ethanol solution for five minutes. Depending on the purpose, the 
cells were stained with the appropriate antibody. In addition, cell nuclei were 
stained with DAPI and cytoplasmic actin was visualized with phalloidin.  
In the former case, after the wash the cells were incubated with Roti-Immunob-
lock for one hour. This was followed by incubation with the primary antibody (Anti-
CCR2 Antibody: 1:500 dilution) for one hour at room temperature or over-night at 
4 °C. The secondary antibody was added in a 1:750 dilution and left again at 
room temperature for one hour. For counterstaining, DAPI and phalloidin were 
used. The cells were incubated with the DAPI/phalloidin mix (300 nM DAPI, phal-
loidin 1:300 dilution) for up to one hour and washed again afterwards. The cover 
slips were mounted on a microscopic slide using DAKO fluorescent mounting 
medium  
For further assessment, confocal microscopy (LSM710 System, Zeiss) was used. 
Fluorescent intensity of the particles was measured and normalized to the fluo-
rescent intensity of DAPI. Comparing the mean florescent intensity in the 633 
channel of different treatment conditions assessed the specific uptake of MSNs 
per cell amount. Three sections on cover slips were chosen in a randomized 
manner and visualized with identical exposure times. Image processing was per-
formed with the IMARIS software. 
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3.2.3 Protein extraction and analysis 
3.2.3.1 Protein extraction 
To extract protein from cell lysates RIPA/Lysis buffer was used. Plated cells were 
washed with ice-cold PBS followed by addition of RIPA/Lysis buffer (with 1x com-
plete protease inhibitor, 70 µl per well in a 6-well plate). The cells were then 
scraped off the dish, transferred into an Eppendorf tube and put on ice. For opti-
mal protein extraction, the lysates were incubated on ice for 30 minutes and vor-
texed every 10 minutes. Cell debris was removed by centrifugation (14 000 RPM, 
4 ˚C, 30 minutes), the supernatant was transferred to a new tube and stored at -
20 ˚C for further analysis. 
 
3.2.3.2 Analysis of protein concentration 
To determine the protein concentration in the lysates, a bicinchoninic acid as-
say (BCA) was performed using the Pierce BCA kit according to the manufac-
ture’s protocol. The samples were diluted 1:10 or 1:5 with PBS 25 µl of this mix-
ture were put in a 96-well plate and 200 µl of the BCA solution provided by the kit 
was added per well. In addition, samples with a known protein concentration were 
assayed on the same plate to determine a standard curve for further calculations. 
After incubation at 37 ˚C for 30 minutes, the absorbance was measured at a 
wavelength of 562 nm with the Sunrise Plate Reader (Tecan). 
 
3.2.3.3 SDS-Page and Western Blot 
For determining the CCR2 expression in the seeded cells, SDS- polyacrylamide 
gel electrophoresis (PAGE) and Western blotting was performed. For SDS-Page, 
Lämmli loading buffer was added to 10-20 µg of protein samples and the mixture 
was incubated at 95 ˚C for 10 minutes. The samples were loaded onto 10% SDS 
PAGE gels (1.5 mm thick) and the electrophoresis was run in running buffer at 
90 V, which was increased to 110 V after the protein left the stacking gel. 
After the electrophoresis, the gels were blotted on a methanol-activated PVDF 
membranes. Transfer buffer was added to the Mini Protean Tetra electrophoretic 
transfer cell and blotting was performed for 90 min at 200 mA. Afterwards the 
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membrane was blocked by incubating it for one hour in Roti Block. The primary 
antibody (CCR2, 1:1000 diluted) was incubated with the blot over night at 4 ˚C. 
After washing 3 times with PBST, the HRP labeled secondary antibody (Anti-
Rabbit, diluted 1:40000) was added and left for one hour. For detection of the 
signal, ECL solution (GE Healthcare, Solution A and B 1:1) was added and the 
blots were developed in the ChemiDoc (ChemiDoc XRS+, Bio-Rad) or the Curix 
60 developer (Agfa). β-Actin was used as a loading control. Densitometry was 
done with the Image Lab Software (Bio-Rad) and the signal was normalized to 
the loading control.    
 
3.2.4 Animal experiments 
All animal experiments were approved by the Regierungspräsidium Oberbayern 
and were performed by Deniz Bölükbas according to the ethical guidelines of the 
Helmholtz Zentrum Munich. The further analysis of the material was performed 
by Deniz Bölükbas and Charlotte Meyer-Schwickerath. 
K-rastm3Tyj mice with lung adenocarcinomas were purchased from Jackson La-
boratory and were further bred in the institute’s animal facilities. The animals were 
kept in a surrounding where constant temperature and humidity were maintained. 
Further, food and water access was given ad libitum.  
 
3.2.4.1 Genotyping 
For genotyping of the newborn animals, tail cuts or ear clips were used. The ma-
terial was lysed with PBND buffer and Proteinase K and heated up to 56°C while 
shaking with 1250 rpm for at least four hours. After spinning the lysate for two 
minutes with 13000 rpm in the centrifuge, 150 µl of the supernatant was put in a 
new Eppendorf tube and stored at 4 °C for further analysis. Subsequently, PCR 
analysis was performed with the reagents summarized in Table 13. To 42 µl of 
the PCR mix, 8 µl of DNA were added and the PCR cycle was performed in the 
Master Cycle as indicated in the table below (Table 14), repeating the cycle 35 
times. 
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Table 13: Components of the PCR mix 
Component Concentration Amount for 50 µl 
PCR buffer 10 x 5 μl 
MgCl2 50 mM 2 μl 
Nucleotides 10 mM 1 μl 
Wt Primer 10 μM 0.5 μl 
Mut Primer 10 μM 1 μl 
Common Primer 10 μM 0.5 μl 
Taq-Polymerase 5 U/μl 0.25 μl 
H2O  31.75 μl 
 
Table 14: PCR cycle 
Step Temperature Time 
Denature 94 °C 1 min 
Annealing 60 °C 2 min 
Polymerase reaction 72 °C 1 min 
 
To determine the size of the gene product and distinguish between mutant and 
wild type animals, agarose gel electrophoresis was performed. For this purpose, 
25 µl of the sample was mixed with DNA loading buffer and a gel electrophoresis 
in a 1.5% agarose gel containing 0.01% Sybr-safe was performed. The gel was 
imaged with the ChemiDoc (Gel imaging system ChemiDoc XRS+, Bio-Rad). 
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3.2.4.2 Hematoxylin and Eosin (H&E) staining 
H&E staining was performed on paraffin sections prepared from the lungs of mu-
tant or wild type mice. For this, the animals were narcotized with 100 mg/ml Ket-
amin and 0.7 mg/ml xylazine per kg body weight and opened with an abdominal 
cut. After exposure of the heart and the lungs, blood was taken with a syringe 
from the heart’s left ventricle. The lungs were perfused with 0.9% sodium chloride 
solution and afterwards fixed by inflation with 4% PFA. Subsequently, they were 
withdrawn from the corps, fixed in 4% PFA at 4 °C overnight. Lungs were further 
processed in the tissue processor (Microtome STP 420D Tissue Processor) and 
embedded in paraffin. 3 µm thick slices were cut with the Hyrax M55 microtome 
(Zeiss), placed on microscopic glass slides and stored at 4 ˚C.  
For staining of the sections, the paraffin was melted and subsequently removed 
by washing the slides in xylene and rehydrating them in different descending eth-
anol dilutions (100%, 90%, 80% and 70%). For H&E staining, the cuts were incu-
bated with hematoxylin for six minutes, washed with tap water, incubated in 0.5% 
eosin G (containing 30 µL glacial acetic acid per 100 ml) for 10 minutes and 
washed with water again. To remove the excess reagent, the slides were washed 
with 80% ethanol and afterwards dehydrated by transferring them into 100% eth-
anol and 100% xylene. The slides were then mounted with Entellan (Merck Milli-
pore) and imaged with the Mirax scanner (Zeiss). Image processing was per-
formed with the Pannoramic viewer software (3DHISTECH). 
 
3.2.4.3 Immunohistochemistry – paraffin cuts 
For immunohistochemistry, the tissue was embedded in paraffin and sectioned 
as described above. Furthermore, the removal of paraffin was also performed as 
described for the H&E staining. After rehydration, the cuts were incubated in a 
30% H2O2 and methanol solution for 20 min for membrane permeabilization and 
blocking of the endogenous peroxidase activity. Antigen retrieval was performed 
with citrate buffer (pH 6) and the slides were heated up to 125 °C for 30 seconds, 
followed by cooling down and washing steps with TBST for further cooling and 
neutralization. For the next steps, the slides were put into Shandon cover plates 
and were first incubated with Rodent Block M for one hour. Afterwards, the 
Materials and Methods 
  39 
primary antibody was added in the desired dilution (e.g., Anti-CCR2: 1:1000) fol-
lowed by incubation with the Rabbit-on-Rodent polymer for another hour. The 
slides were incubated with AP substrate solution (Vulcan fast red) for 12 minutes 
and were finally counterstained hematoxylin. Excess reagent was removed by 
dipping the slides in 95% ethanol. Before mounting, the slides were dehydrated 
in different ascending solutions of ethanol and xylene (95% ethanol, 100% etha-
nol and 100% xylene). The slides were mounted and imaged as described for the 
H&E staining above. 
 
3.2.4.4 3D lung tissue cultures  
For ex vivo 3D lung tissue cultures (3D-LTC), K-ras mutant or wild type animals 
were sacrificed as described above. After perfusing the lungs with 0.9% NaCl, 
the lungs were inflated with 1-2 ml of 2% agarose. The lungs were then resected 
from the corps and kept in DMEM/F12 media on ice until further processing.  
For cutting the lungs into 300 µm thick slices, a vibratome (Hyrax V50, Zeiss) was 
used and the tissue cultures were incubated with DMEM/F12 containing 10% 
FCS, 1% P/S and 1% Amphotericin B for MSNs uptake analysis. For this purpose, 
the 3D-LTC were treated with different kinds of MSNs (50 µl/ml) labeled with Atto 
633 and kept in the incubator for 12 hours. After washing three times with PBS, 
one time with NaCl pH 3 and three times with PBS, the lung slices were fixed with 
70% Ethanol. After another wash with PBS, the tissue was stained with DAPI and 
phalloidin by incubating the slices in the solutions for one hour. This reaction was 
terminated by washing with PBS and mounting the slices onto microscopic slides 
with DAKO Fluorescent mounting medium. The uptake was measured with con-
focal microscopy by comparing the mean florescent signal in the 633 channel to 
the DAPI signal. For the K-ras mutated animals, three healthy and three tumorous 
regions per condition were selected in a randomized manner and imaged with 
the same acquisition settings. Image processing was performed with Imaris Soft-
ware, Bitplane. 
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3.2.4.5 Intratracheal administration of the MSNs 
For assessing the bio-distribution of MSNs after application into the lungs, 50 µl 
of MSNs were intratracheally applied to the mice. For the procedure, the mice 
were narcotized by intraperitoneal administration of MMF (0.2 mg/ml Me-
detomidin, 2.0 mg/ml Midazolam, 0.02 mg/ml Fentanyl per kg body weight) and 
the particles were administered through a custom made tubus inserted through 
the trachea. After the instillation, narcosis was antagonized by giving 0.29 mg/ml 
Atipamezole, 0.059 mg/ml Fumazenil and 0.14 mg/ml Naloxone per kg body 
weight subcutaneously and the animals were monitored closely. 
After three days, the animals were sacrificed and the organs were harvested as 
described above. The lungs were perfused with 0.9% sodium chloride solution 
and afterwards inflated with O.C.T. (Sakura – Tissue Teck) through the trachea. 
After the lungs were disconnected from the mice corpse, they were embedded in 
O.C.T and stored at -20 ˚C. The procedure was continued by harvesting the liver, 
kidney, spleen and brain.  
 
3.2.4.6 Immunofluorescence staining on cryosections 
For evaluating the uptake of MSNs in the treated mice, all the organs were em-
bedded in OCT, frozen in -20 ˚C and cut with the Hyrax C50 Cryotome (Zeiss) 
into 5 µm thick slices. For the lungs, each lobe was embedded and cut separately 
from the others.  
The cuts were then fixed by incubating them in 70% ethanol and washed with 
PBS afterwards. For the first uptake analysis, DAPI and phalloidin were used to 
stain the tissue. For this, the slides were incubated for one hour with 300 nm 
DAPI and phalloidin (1:300 diluted) and again washed with PBS. For mounting of 
coverslips, DAKO fluorescent mounting medium was used and the slides stored 
at 4˚C protected from light.  
As MSNs uptake in specific cells was analyzed, staining of cell receptors were 
prepared. For this, the sections were fixed by incubation in 4% PFA. They were 
afterwards washed with PBS + 0,1% Triton-X once, followed by two washes with 
pure PBS. For blocking they were incubated in RotiBlock with 5% Goat serum for 
1.5 hours. The primary antibody (CCR2: 1:500; CD68 1:50) was left on the cuts 
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overnight, followed by the secondary in a dilution of 1:750. For counterstaining, 
DAPI and phalloidin were used as described above. The cuts were again 
mounted with DAKO fluorescent mounting medium and stored at 4°C. 
The stained slides were imaged with the LSM imaging system (Zeiss), three pic-
tures of each organ were taken in a randomized manner and the uptake was 
assessed by measuring the fluorescent intensity (Imaris Software, Bitplane) of 
Atto 633 (MSNs’ signal) and normalizing it to the DAPI signal. For the lungs, three 
pictures of healthy regions and three pictures of tumor regions were taken per 
lung lobe. 
 
3.2.5 H&E staining of human resections 
Human tissue samples were kindly provided by the Asklepsios Biobank for Lung 
Diseases, Gauting, Germany. The obtained material was embedded in paraffin 
and sections were stained as described above in chapter 3.2.4.2.  
 
3.2.6 Statistical analysis 
For statistical analysis one sample t-tests were used. All statistical analysis was 
performed with the GraphPad Prism Software (Version 5). Significance was indi-
cated as * p<0.05.  
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4 Results 
4.1 Expression of CCR2 in human and mouse lung tissue 
In order to confirm published expression data on CCR2 as a potential targeting 
receptor for nanoparticle mediated drug delivery, increased expression of CCR2 
in primary human lung tumors and in the mouse model of K-ras-induced adeno-
carcinomas of the lung was validated.  
 
4.1.1 CCR2 is overexpressed in human lung tumors 
To confirm the overexpression of CCR2 in human lung adenocarcinomas, im-
munohistochemical staining of three human lung adenocarcinoma samples for 
CCR2 was performed. As seen in two representative stainings in Figure 4-1, in-
deed, tumor sections (A) showed an increase in CCR2 expression (red signal) in 
comparison to tumor free regions of the same patient’s sample (B). Tumor free 
regions only showed a few positive cells in contrast to tumor regions where mul-
tiple positive cell clusters could be observed. In addition, a positive staining in the 
stromal cells around tumor cell nests was observed (A, Patient B). The negative 
control included an unspecific IgG antibody and proved specificity of the CCR2 
staining. This indicates that the receptor might be a suitable target for future cell 
specific treatments as proposed before (Qian et al., 2011; Schmall et al., 2015; 
Wolf et al., 2012)  
 
4.1.2 Tumors of K-ras mutant animals express CCR2 
As an appropriate mouse model, the K-rastm3yj mouse model from The Jackson 
Laboratory was evaluated, which shows early lung tumor development in 100% 
of the heterozygous animals (Johnson et al., 2001). As the tumor onset in this 
transgenic line develops by chance (Johnson et al., 2001) this mouse model mir-
rors the physiological condition in humans and represents the most appropriate 
transgenic lung cancer mouse model to date (Bolukbas & Meiners, 2015). 
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Figure 4-1 CCR2 is overexpressed in human lung tumors 
A+B) Representative IHC staining of human lung tumors (A) and tumor free regions (B). Pictures 
of tumor and tumor free regions were chosen from two different patients. The slides were stained 
with an anti-CCR2 antibody (pink signal) and counterstained with hematoxylin. IgG Controls were 
performed to control for unspecific staining. n=3  
 
To estimate tumor development and growth, paraffin embedded lung sections of 
13 mice varying in age (6 weeks to 29 weeks) and gender (8 males and 5 fe-
males) were stained with Hematoxylin and Eosin. As the young animals (6 weeks 
after birth) already showed tumor lesions, an early onset of tumor growth can be 
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assumed. In addition, the pictures showed a heterogeneous tumor growth as the 
number of tumor lesions varied in between mice from the same age (Figure 4-2 
B Nr. 154 and 155) and there was a high diversity in tumor size. This can be very 
well observed in mice Nr. 150 and 152 of Figure 4-2 B, as they have the same 
age but the size of the tumor lesions differs significantly.  
 
 
Figure 4-2 Lung tumors from K-ras mutated mice differ in size and number 
A) Table with age and gender of K-ras mutated animals. B) Overview of HE stained lung sections 
of the different animals. Darker stained areas indicate tumor lesions. The pictures were kindly 
provided by Deniz A. Bölükbas. 
 
To confirm overexpression of CCR2 in the tumors of the described mouse model, 
lung sections of K-ras mutated and wildtype mice were stained with an anti-CCR2 
antibody. As shown in a representative section in Figure 4-3, tumors showed a 
clear signal in the cancerous areas, indicating an overexpression of CCR2 in tu-
mors in comparison to tumor free regions and wild type animals. However, no 
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statement regarding the cell type expressing CCR2 could be made from the lo-
calization of the staining. CCR2 might therefore be expressed on cancer cells as 
well as on tumor stromal cells. Due to the positive CCR2 expression and the 
already named advantages of the mouse model, it was chosen for further exper-
iments. 
 
 
Figure 4-3 CCR2 is overexpressed in lung tumors from K-ras mutated mice 
Fig: Representative IHC staining of K-ras mutant and wildtype lungs. The slides were stained with 
an anti-CCR2 antibody (pink signal) and counterstained with Hemalaun. IgG Controls were per-
formed for each staining. K-ras mutant and wildtype lungs: n=3. 
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4.2 Synthesis and characterization of mesoporous silica nano-
particles 
As CCR2 was overexpressed in human and mouse lung tumors, it was validated 
as an adequate target for cell-specific treatment. For this purpose, particles were 
designed to be taken up by cancer cells and tumor-associated macrophages 
through endocytosis and release their cargo inside the cell.  
The particles used in this study consist of a SiO2 mesoporous core structure, 
which is sealed with the bulky avidin protein attached to the pore openings by a 
pH responsive linker (Cauda et al., 2009; Schlossbauer et al., 2009). In addition, 
a ligand for receptor-mediated uptake was added (Figure 4-4). In an acidic envi-
ronment such as the endosomes, the pH-responsive linker is broken, the avidin 
caps are detached and the cargo can be released from the particle (Figure 4-4). 
 
 
Figure 4-4 Schematic representation of the CCR2-targeted MSNs 
The mesoporous silica nanoparticle (MSN) is sealed with an avidin cap (dark green) attached to 
a pH-responsive linker (red). A ligand (purple) is added for receptor-mediated cellular uptake. The 
particle can be loaded with a cargo (yellow) and labeled with a florescent agent (light green). 
Figure kindly provided by Deniz Bölükbas 
 
 
4.2.1 CCR2-targeted MSNs and control particles do not differ in size 
For the design of CCR2-targeted MSNs, a CCR2 antagonist (ECL1 (C) inverso) 
was used as a ligand (Auvynet et al., 2016). As controls, a non-targeted particle 
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(AVI) and a scrambled control particle, in which the ligand contains the same 
amino acids as the CCR2 antagonist but is arranged in a scrambled sequence, 
were chosen (Table 15). 
 
Table 15: MSNs used in the studies 
Particle name Ligand Amino Acid Sequence 
of Ligand 
AVI No ligand  
CCR2-targeted ECL1 (C) inverso CKLFTGL 
Scrambled con-
trol 
Scrambled ECL1 (C) inverso CTLLGFK 
 
To assess whether the particles show an increase in size when a ligand is added 
to the surface, a DLS measurement was performed. Figure 4-5 shows DLS meas-
urement of two representative syntheses of AVI, CCR2-targeted and scrambled 
control particles. The majority of the particles were found to be similar in size 
differing between 90 nm and 200 nm, shown by the peek in the size curve. Thus 
adding a CCR2 ligand and a scrambled control ligand to the particle surface does 
not significantly increase the particle size.  
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Figure 4-5 MSNs are 90-200 nm in size 
DLS measurement of two representative particle syntheses of AVI, CCR2-targeted and scram-
bled control particles. The experiment was repeated 4 times in total. The measurement was per-
formed and data was kindly provided by Stefan Datz. 
 
4.2.2 MSNs release their cargo in an acidic environment  
As the particles were sealed with a pH-responsive linker, cargo release was 
tested in response to different pH environments. This mechanism was tested by 
loading the particles with propidium iodide (PI) and measuring the absorbance at 
500 nm wavelength of the surrounding solution depending on the pH. In the neu-
tral environment (pH 7), the particles stayed sealed over 48 hours and PI was not 
released. However, when the surrounding pH dropped to 5, the particles were 
cleaved, PI was set free and the absorbance changed (Figure 4-6). In addition, 
the cleaving process increased over time with a maximum at 48 hours. As the pH 
found in the endosomal compartment after cellular uptake is acidic, the observed 
mechanism can be transferred to the cell leading to the assumption that the pH-
responsive linker works similar releasing the particles’ cargo after cellular uptake 
via endocytosis. 
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Figure 4-6: CCR2-targted MSNs release their cargo in an acidic environment 
Particles were loaded with PI and absorbance at 500nm wavelength was measured, two repre-
sentative syntheses are shown. The measurement was performed by Stefan Datz. 
 
4.3 MSNs uptake by CCR2-expressing cells in vitro 
As the synthesized particles showed a pH-responsive release of their cargo, the 
cell-specific uptake of CCR2-targeted MSNs was investigated. For this purpose, 
in vitro uptake experiments were performed in a suitable cell line that expressed 
high levels of CCR2. 
 
4.3.1 MHS cells express CCR2  
MHS, a murine alveolar macrophage cell line, mirrors alveolar macrophage func-
tion in the lung (Mbawuike & Herscowitz, 1989). CCR2 expression on MHS cells 
and A549 cells, a common lung cancer cell line (Giard et al., 1973), was investi-
gated by Western blotting for CCR2. Detection of β-actin was used as a loading 
control. As seen in Figure 4-7 A and B, staining of MHS protein samples showed 
three distinct bands differing between 48 and 30 kDa in size, indicating two 
isoforms (two bands between 35 and 48kDa) and a glycolyzed form of CCR2 
(Charo et al., 1994; Deshmane, Kremlev, Amini, & Sawaya, 2009). A549 cells 
showed a lower expression of CCR2 compared to MHS cells, which was validated 
by quantification of the signal relative to β-actin. 
Immunofluorescence staining of MHS cells confirmed the expression of the re-
ceptor as a CCR2-specific staining was revealed on every cell (Figure 4-7 C). 
Image processing was performed to estimate whether the receptor is equally 
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distributed on the cell surface. The green signal represents the receptor, which 
showed a homogeneous distribution around the cell nuclei stained in blue (Figure 
4-7 C). As these results indicated CCR2 expression on MHS cells, this cell line 
was used for subsequent uptake experiments. 
 
Figure 4-7 MHS cells express CCR2 
A: Western blot analysis of CCR2 expression in MHS and A549 cells. Three different bands indi-
cate two isoforms and a glycolyzed form (Charo et al., 1994; Deshmane et al., 2009). B: Quanti-
fication of Westernblot analysis, n=3 + SEM C: Representative IF staining of MHS cells for CCR2 
receptor and image processing with Imaris software to show distribution of the signal, Picture was 
taken with 63x magnification.  
 
4.3.2 CCR2-targeted MSNs are taken up by MHS cells 
The first step was to evaluate the uptake of CCR2-targeted MSNs in comparison 
to scrambled control and AVI particles. MHS cells were treated with particles la-
beled with Atto 633 for one hour and were fixed and stained with DAPI and phal-
loidin afterwards. To avoid the detection of particles that unspecifically stick to 
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the cell surface, cells were extensively washed with PBS and NaCl pH 3 solution 
after the MSNs treatment.  
As seen on the images in Figure 4-8 A, measured with confocal microscopy the 
fluorescence intensity of CCR2-targeted MSNs was higher than the signal of the 
control particles, which was also confirmed by quantification of the mean flo-
rescent intensity of each particle type (Figure 4-8 B). These results indicated a 
slightly higher uptake of CCR2-targeted particles in MHS cells compared to 
scrambled control and AVI particles (p = 0.0716).  
 
 
Figure 4-8 Immunofluorescence staining: CCR2-targeted MSNs are taken up by MHS cells 
A: Representative immunofluorescence staining of MHS cells treated with MSNS. The images 
are taken with a 63x magnification. B: Quantification of MSN uptake measured with Imaris Soft-
ware. Mean florescent intensity of the particles is normalized to mean florescent intensity of DAPI 
and the MSN uptake is normalized to AVI, n=4 (3 different particle syntheses, 4 different treat-
ments) + SEM.  
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In addition, FACS analysis was performed to quantify the uptake using a second 
method. For this, MHS cells were treated with Atto 488 labeled particles for one 
hour and median fluorescent intensity was assessed. Indeed, previous results 
were confirmed as CCR2-targeted uptake was significantly (p < 0.05) increased 
(3.75 fold) in comparison to AVI particles and 9 fold in comparison to scrambled 
control particles (Figure 4-9). 
 
 
Figure 4-9 Flow cytometry: CCR2-targeted MSNs are taken up by MHS cells 
A: flow cytometry analysis of MHS cells treated with MSNs, median florescent intensity of Alexa 
flour 488 was measured. B: Quantitative analysis of flow cytometry data, median fluorescent in-
tensity was measured and normalized to AVI, * indicates p<0.05, n=4 + SEM. 
 
When MHS cells, which had been treated with CCR2-targeted and scrambled 
control MSNs, were stained with an anti-CCR2 antibody an overlap of the recep-
tor signal (green) and CCR2-targeted particle signal (red) was observed, indicat-
ing a co-localization and thus binding of the CCR2-targeted particle to the CCR2 
receptor. However, this was also true for the scrambled control MSNs, therefore 
questioning a valid specific binding of CCR2-targeted MSNs to the receptor 
(Figure 4-10 A).  
Nevertheless, image processing showed a homogeneous distribution of the 
CCR2-targeted MSNs around the cell nuclei and a close to complete uptake, as 
only few red particles stuck outside of the green signal, which was obtained by 
intracellular staining of the actin cytoskeleton with phalloidin (Figure 4-10 B). The 
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staining obtained with scrambled control particles, by contrast, revealed that 
these particles were mainly localized outside the cells in an area not stained with 
phalloidin or DAPI. They remained on the cell surface and in between the cells in 
greater numbers compared to the CCR2-targeted MSNs (Figure 4-10 C). This 
repeatedly indicated a more specific uptake of CCR2-targeted MSNs than of con-
trol particles.  
 
 
Figure 4-10 CCR2-targeted and scrambled control MSNs co-localize with CCR2 
A: representative immunofluorescence staining of MHS cells treated with CCR2-targeted MSNs 
(red) or scrambled control MSNs (red) and stained for the CCR2-receptor (green). The images 
were taken with a 63x magnification. B+C: Image processing performed with the Imaris software. 
Blue spheres represent DAPI, green surfaces phalloidin and red spheres MSNS signal. 
 
Concluding, in vitro experiments displayed cell specific uptake of CCR2-targeted 
MSNs in MHS cells. Targeted particles were taken up in greater number com-
pared to AVI and scrambled control particles (Figure 4-8, Figure 4-9), showed a 
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co-localization with the CCR2 receptor (Figure 4-10) and were taken up into the 
cell as revealed by co-localization with the intracellular phalloidin signal (Figure 
4-10). However, a specific binding to the CCR2-receptor is still questionable. 
 
4.3.3 CCR2-targeted MSNs localize at a different part of the cell than AVI MSNs 
The localization of AVI and CCR2-targeted MSNs on the cells was also investi-
gated. Cells were simultaneously treated with both particles, which had been la-
beled with different florescent dyes, washed with PBS and NaCl pH 3 and stained 
with DAPI subsequently. As seen in Figure 4-11, AVI particles are distributed over 
the whole cell surface whereas CCR2-targeted MSNs seem to localize at specific 
spots on the cell surface. This leads to the assumption that the binding site and 
thus uptake site of the particle types differs depending on the presence of the 
CCR2 ligand.  
 
 
Figure 4-11 CCR2-targeted MSNs localize to a different part of the cell than AVI MSNs 
Representative immunofluorescence staining of MHS cells treated with AVI (green) and CCR2 
(red) targeted MSNs, experiments were repeated three times, three pictures of each microscopic 
slide were taken, one representative picture is shown. The images were taken with a 63x magni-
fication. 
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4.4 MSN uptake in 3D lung tissue cultures 
As it was shown in vitro that CCR2-targeted MSNs were taken up better than 
control particles by MHS cells, an ex vivo situation was used to test the particles 
in a more physiological condition. 3D lung tissue cultures (3D-LTC) are 300 to 
500 µm thick slices of living lung tissue and can be held in culture for five days 
as cells remain viable and functional (Uhl et al., 2015). Therefore, these tissue 
cultures are an established ex vivo model for lung physiology and pathology. In 
addition, it has been shown that nanoparticles are taken up by the tissue in the 
3D-LTC (Sabine H. van Rijt et al., 2015). Tumors of K-ras mutated animals show 
an increased expression of CCR2, which led to the idea of generating 3D-LTC of 
K-ras transgenic animals to test the targeted MSNs in an ex vivo situation. For 
this purpose, 300 µm think slices of lungs from K-ras mutant and wild type mice 
were incubated with CCR2-targeted and AVI MSNs for 12 hours and subse-
quently fixed and imaged for analysis. 
 
4.4.1 Lung tumors in 3D lung tissue cultures of K-ras mutant animals do 
not show an increased uptake of CCR2-targeted MSNs 
To assess preferential uptake of CCR2-targted MSNs by tumor cells and TAMs 
compared to healthy cells in order to analyze tumor-cell specific targeting, uptake 
of fluorescently labeled particles was monitored by confocal microscopy. Uptake 
of CCR2-targeted MSNs in K-ras mutant 3D-LTC was compared to uptake of AVI 
control particles in K-ras mutant 3D-LTC. For this purpose, the lung sections were 
incubated with the particles labeled with Atto 633 (red signal) for 12 hours and 
washed extensively with PBS and NaCl pH3 afterwards to discard excess parti-
cles. The sections where then counterstained with DAPI and phalloidin. 
However, a difference of the particle signal between the tumor and tumor free 
regions in both particle types was not observed, indicating no uptake difference 
between the tumor and tumor free regions (Figure 4-12 A and B). Nonetheless, 
a difference in general uptake between CCR2-targeted and AVI control particles 
was observed. When comparing tumor-specific uptake of CCR2-targeted parti-
cles to tumor-specific uptake of AVI particles, a higher total signal of CCR2-
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targeted particles was measured. This was also witnessed when comparing up-
take in tumor free regions between the two particle types (Figure 4-12 A and B).  
 
 
Figure 4-12 Lung tumors in 3D-LTC of K-ras mutated animals do not show an increased 
uptake of CCR2-targeted MSNs 
A: representative pictures of tumor and tumor free areas of MSN treated 3D-LTC from K-ras mu-
tant mice. The dashed line indicates the tumor. Pictures were taken with a 10x magnification. B: 
Quantitative analysis of MSN uptake in the tumor and tumor free region. Mean florescent signal 
of the particles is normalized to DAPI and the MSN uptake is normalized to AVI, n=3 (one particle 
synthesis, 3 treatments) + SEM. C: Image processing of K-ras mutant 3D-LTC treated with CCR2-
targeted MSNs. Blue spheres represent DAPI, red spheres the MSN signal. 
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Yet, a limitation of the experiment was revealed when 3D scanning of the cultures 
via LSM showed that both particle types were more likely to stay on top of the 
lung slices and did not penetrate deeper regions (Figure 4-12 C) showing no 
penetration of the particles in the 3D-LTC. Thus it is questionable whether 3D-
LTC are a suitable model for assessing targeted and non-targeted nanoparticle 
uptake in tumor models.  
 
4.4.2 3D lung tissue cultures of wildtype animals show a reduced uptake 
of CCR2-targeted MSNs 
The treatment of the K-ras mutant 3D-LTC showed a higher uptake of CCR2-
targeted MSNs in general (in tumor and tumor free regions). To investigate 
whether this is due to the particle design or to a higher amount of CCR2 express-
ing cancer cells and tumor-associated macrophages, 3D-LTC of wild type ani-
mals were treated as described above. Strikingly, after washing the 3D-LTC, the 
signal of CCR2-targeted MSNs was decreased in comparison to the signal of AVI 
control particles in 3D-LTC of wild type animals (Figure 4-13 A and B). This might 
indicate a decreased uptake of the CCR2-targeted MSNs in comparison to AVI 
control particles, thus suggesting that the higher uptake in the 3D-LTC of K-ras 
mutant animals might be due to a higher density of CCR2-expressing tumor cells 
and macrophages in lungs of K-ras mutant animals.  
However, AVI control particles seem to agglomerate more in the wt 3D-LTC 
(Figure 4-13 A and B) and once again it was observed that the particles were not 
equally distributed throughout the tissue culture but rather remained on the upper 
side (Figure 4-13 C) as described above for the K-ras mutant 3D-LTC. Hence, 
the mentioned problems with this ex vivo model led to the conclusion that 3D-
LTC are not a valid model to assess differential uptake of cell-targeted nanopar-
ticles. 
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Figure 4-13: 3D-LTC of wildtype animals show a decreased uptake of CCR2-targeted MSNs 
A: representative pictures of wildtype 3D-LTC treated with MSNs, pictures were taken with a 10x 
magnification. B: Quantification of MSN uptake in wildtype 3D-LTC. Mean florescent signal of the 
particles is normalized to DAPI and the MSN uptake is normalized to AVI, n=3 (one particle syn-
thesis, 3 treatments) + SEM. C: Image processing with Imaris Software to show the particle dis-
tribution. The blue spheres represent DAPI, the red spheres the MSN signal. 
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4.5 MSNs uptake in vivo 
To investigate the bio-distribution and uptake specificity of CCR2-targeted MSNs 
particles compared to control MSNs in vivo, we assessed differential uptake of 
the particles after local application into the lung. K-ras mutant animals were 
treated with a single administration of CCR2-targeted MSNs or AVI control parti-
cles, both labeled with Atto 633, through the trachea. After three days, the lungs, 
liver, spleen and kidney were harvested to evaluate the distribution of the applied 
MSNs and the uptake specificity (Figure 4-14).  
 
 
Figure 4-14 Treatment scheme – Intratracheal administration of MSNs 
Edited from clodrosome.com/animal-injection 
 
4.5.1 Intratracheally administered MSNs are not systemically distributed 
into peripheral organs 
To evaluate whether CCR2-targeted and AVI control particles remain in the lung 
or enter the bloodstream and systemically distribute into peripheral organs, lungs, 
liver, spleen and kidney of each animal were examined. For this purpose, for each 
animal three cuts of each organ were stained with DAPI and phalloidin and sub-
sequently pictures of three random sections of each cut were taken. As shown 
with a representative image in Figure 4-15, immunofluorescence signal of CCR2-
targeted particles (red) and AVI control particles (red) was assessed and a pro-
nounced signal was observed in the lungs compared to the other organs of the 
treated animals. This indicates no significant leakage/transport via the blood into 
other organs for both particle types (Figure 4-15). 
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Figure 4-15 MSNs do not significantly leak into the bloodstream when they are adminis-
tered locally into the lung 
Representative IF staining of lungs, liver, spleen and kidney of K-ras mutant animals treated with 
AVI or CCR2-targeted MSNs. n=5, shown pictures were taken with a 20x magnification. 
  
4.5.2 CCR2-targeted and control MSNs are taken up in the lung but show 
heterogeneous cellular distribution in vivo  
For analyzing whether CCR2-targeted and AVI control MSNs reach all lung lobes 
and whether an active targeting could be observed, all lungs of the treated ani-
mals were dissected and cut into the five lobes. The lobes were then cut into 5 
µm thick slices and three slices of each lobe were stained. Three random images 
of tumor and three random images of tumor free regions were taken and analyzed 
subsequently.  
When analyzing the different lobes of each treated K-ras animal, it became obvi-
ous that the CCR2-targeted and AVI control MSNs reached all lung lobes, as 
nanoparticles were observed in alveoli of each lobe. In addition, MSNs were de-
tected in tumor and tumor-free regions of the tissue. However, a heterogeneous 
distribution was observed as the density of the particles differed throughout the 
lobes of one lung and in between different animals (Figure 4-16).  
 
Results 
  61 
  
Figure 4-16 MSN uptake into the lung of K-ras mutant mice is heterogeneous 
IF images of lungs from different K-ras mutant mice intratracheally treated with CCR2-targeted 
(A) or AVI control (B) MSNs. n=5 (For each group, 5 animals were treated, each lobe of the lungs 
was conserved and cut separately. Three pictures of tumor and three pictures of tumor-free re-
gions were taken per mouse. For each example shown, pictures were chosen from the same 
lobe.) Images were taken with a 20x magnification. 
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Comparing the general uptake of CCR2-targeted to that of AVI control particles, 
no significant difference between the two types of MSNs could be observed 
(Figure 4-16 A and B). In addition, no trend in the differential uptake between 
tumorous and tumor free regions for each particle type could be validated (Figure 
4-16). This indicates that the CCR2 targeting of cancer cells and tumor-associ-
ated macrophages does not improve tumor targeting specificity. CCR2-targeted 
MSNs are taken up in a similar manner as AVI control particles and do not spe-
cifically target tumors upon intratracheal instillation.  
 
4.5.3 The uptake of CCR2-targeted and control MSNs in vivo varies be-
tween tumors depending on their size  
Having a closer look on the images of tumor regions in the experimental setup 
describes above, it became obvious that CCR2-targeted particles are taken up 
better by small tumors in comparison to larger ones and that there is a higher 
uptake in the tumor edge regions (Figure 4-17 A). As this could also be detected 
for AVI control particles (Figure 4-17 B), it demonstrates that the specific targeting 
of K-ras mutant lung tumor cells with CCR2-targeted nanoparticles was not 
achieved. In general: tumor cells take up nanoparticles more avidly than healthy 
lung cells.  
However, no quantitative analysis of the uptake could be performed, as the dis-
tribution of the particles in between the lobes and the lungs was too heterogene-
ous and there was no option to measure the tumor volume and size from a 2D 
picture and correlate this to the particle uptake. In addition, lungs varied in num-
ber and size of tumor tissue.  
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Figure 4-17 Uptake of MSNs in lung tumors is dependent on tumor size 
Representative IF stained lung sections of K-ras mutant mice treated with MSNs intratracheally. 
Pictures are representative for three tumor regions from each mouse. For each treatment condi-
tion shown above pictures are chosen from the same lobe.  
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4.5.4 CCR2-targeted and AVI control MSNs are taken up by CCR2 positive 
cells in K-ras mutant mice when administered intratracheally 
Even though tumor specific targeting with CCR2-targeted MSNs was not 
achieved, we wanted to evaluate whether CCR2-targeted MSNs are taken up 
specifically by CCR2-positive cells in tumor free regions. Therefore, three cuts of 
each lobe were stained for the CCR2 receptor, three random images of tumor 
free regions of each cut were taken and co-localization of the receptor signal and 
the Atto 633 labeled MSNs was evaluated.  
The staining revealed a co-localization of CCR2-targeted Atto 633 labeled MSNs 
(white) and the CCR2 receptor (green) (Figure 4-18) in large cells situated in the 
alveolus on top of the endothelial cells. From the localization of these cells within 
the alveolus, it can be hypothesized that these cells are alveolar macrophages, 
phagocytic cells that take part in the pulmonary defense mechanisms (Welsch & 
Deller, 2014), which are positive for CCR2 staining in the lungs of K-ras mutant 
mice. Nonetheless, this co-localization of the CCR2-receptor (green) and the 
MSN signal (white) was also seen for AVI control particles in similar cells (Figure 
4-18), indicating again a non-specific uptake of MSNs when given intratracheally 
to lungs of K-ras mutant mice. 
 
4.5.5 CCR2-targeted and AVI MSNs are taken up in CD68 positive macro-
phages in vivo 
To confirm the hypothesis that the MSN-phagocytosing cells mentioned above 
are alveolar macrophages, a staining of CD68, a marker for cells of the macro-
phage lineage including alveolar macrophages, was performed and co-localiza-
tion with Atto 633 labeled MSNs was evaluated consecutively. For this purpose, 
again three cuts of each lobe were stained and images of three random tumor 
free regions were taken.  
The staining supported the described cells as alveolar macrophages and re-
vealed enhanced accumulation of MSNs in these cells in tumor free regions of 
intratracheally treated K-ras mutant lungs (Figure 4-19). However, this was not 
only true for CCR2-targeted MSNs but also for AVI control particles as demon-
strated in Figure 4-19. In both treatment conditions co-localization of Atto 633 
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labeled MSNs (white) and CD68 receptor staining (green) was observed, indicat-
ing that both, CCR2 targeted and AVI control MSNs are taken up by the alveolar 
macrophages as part of their physiological foreign-body response function 
(Welsch & Deller, 2014). 
 
 
Figure 4-18 CCR2-targeted and AVI control MSNs accumulate in CCR2 positive cells in 
lungs of K-ras mutant mice 
Representative IF staining for CCR2 in lungs of K-ras mutant mice treated with CCR2-targeted 
MSN or AVI control MSN intratracheally. n=4 (Lungs of four different mice for each treatment 
condition were stained and pictures of three different tumor free regions of each slide were taken.) 
Representative images are shown above. Images are taken with a 63x magnification. 
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Figure 4-19 CCR2-targeted and AVI control MSNs accumulate in CD68 positive macro-
phages in lungs of K-ras mutant mice  
Representative IF staining for CD68 positive cells in tumor free regions of K-ras mutant lungs 
treated with MSNs intratracheally. For each mouse (n=4), pictures of three different regions were 
taken and representative images are shown above. Images are taken with a 63x magnification. 
 
Data was obtained in collaboration with Deniz Bolükbas and was partly published in 
Bölükbaş, D. A. (2017). Development of novel nanoparticle-based therapeutics for treat-
ment of lung cancer. München. 
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5 Discussion 
The aims of this thesis were to validate CCR2-targeted MSNs for lung cancer 
therapy by evaluating the cell specific uptake of CCR2-targeted MSN in vitro and 
in a lung cancer mouse model in vivo. In this context, first of all published data 
regarding the elevated expression of CCR2 in lung tumors was confirmed 
(Cortez-Retamozo et al.; Fridlender et al., 2011; Hiratsuka et al., 2013; Qian et 
al., 2011; Schmall et al., 2015) (Figure 4-1, Figure 4-3). In addition, this study 
provides in vitro proof-of-concept evidence that CCR2 can be used as a cell-
specific receptor for targeted delivery of MSNs to CCR2 overexpressing cells as 
cell-specific targeting in an in vitro setup was successfully demonstrated (Figure 
4-8, Figure 4-9). However, similar results could not be confirmed in vivo, as there 
was no increased cellular uptake of CCR2-targeted particles in lung tumors after 
local delivery of targeted nanoparticles to the lung (Figure 4-16, Figure 4-17). In 
contrast, alveolar macrophages were taking up targeted as well as non-targeted 
MSNs to a similar extent (Figure 4-19).  
 
5.1 Discussion of experimental setup 
5.1.1 Testing CCR2 targeted MSNs in vitro 
When treating CCR2 expressing MHS cells with the synthesized MSNs we ob-
served a higher uptake of CCR2-targeted particles than of AVI control or scram-
bled control particles. These findings were confirmed by confocal microscopy as 
well as FACS analysis (Figure 4-8, Figure 4-9). Interestingly, scrambled control 
particles were taken up by MHS cells in the FACS analysis experiments to a 
lesser degree than in the immunofluorescence staining experiments, which were 
assessed by confocal microscopy. As the incubation time and washing proce-
dures were the same for both experimental setups, the technical procedures ap-
pear to play an important role. As stated above, scrambled control particles were 
observed to stick to the cell membrane to a greater extend and were not taken 
up in the same way as CCR2-targted MSNs (Figure 4-10). The measurement by 
confocal microscopy may have included these particles. We were only able to 
measure the complete signal of all particles on the slide and normalize this to our 
cell signal. Thus, particles localized next to cells may have been added to this 
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calculation. During the FACS analysis, these particles were not counted as only 
the overlay of the florescent signal of the particles with the florescent signal of the 
cell was measured and therefore free floating particles were excluded (Gottstein, 
Wu, Wong, & Zasadzinski, 2013). However, membrane bound particles were in-
cluded in both experiments (Meindl, Öhlinger, Ober, Roblegg, & Fröhlich, 2017). 
In addition, due to technical reasons, FACS analysis can include a higher number 
of cells leading to more differentiated results (Gottstein et al., 2013; Meindl et al., 
2017).  
 
5.1.2 Testing CCR2-targeted MSNs ex vivo 
Using the 3D lung tissue cultures (3D-LTC) as an ex vivo model for testing an 
active targeting nanotherapy approach revealed some complications. In the past, 
our group was able to translate this ex vivo model to tumor lungs of K-ras mutant 
mice and non-targeted stimuli-sensitive MSNs were successfully evaluated for 
their effectiveness (Sabine H. van Rijt et al., 2015). However, in the former ex-
periments it already became obvious that MSNs are immobilized on top of the 
tissue and a deep penetration of the tumor is difficult to achieve in these settings 
(Sabine H. van Rijt et al., 2015). This was confirmed by our recent study for 
CCR2-targeted and control MSNs (Figure 4-12). Even though 3D-LTC are viable 
for at least five days and the organ structure is preserved (Uhl et al., 2015), the 
static condition of the experimental setup enhances particle aggregation, thus 
making it more difficult for the particles to diffuse into the tissue. In addition, the 
tumor tissue has a higher density and rigidity compared to the healthy alveolar 
tissue and the dense extracellular matrix impedes penetration of the particles 
(Jain & Stylianopoulos, 2010; Pickup, Mouw, & Weaver, 2014; Popović et al., 
2010; Wilhelm et al., 2016). In the active targeting approach used here, the engi-
neered nanoparticles need to be in direct contact with the target cell. Sufficient 
penetration of the tissue is thus a prerequisite for effective and cell-specific tar-
geting. This differs from the study by Van Rijt et al., where MSNs, which release 
their cargo into the extracellular matrix by a secreted enzyme (MMP-9), were ap-
plied and deep penetration of the particles to the tumor was thus not necessary. 
In conclusion, 3D-LTC do not appear as a suitable model to assess cell-specific 
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targeting of CCR2-targeted MSNs due to inherent technical problems in tumor 
models.  
 
5.1.3 Testing CCR2-targeted nanoparticles in vivo 
Recently there has been a major debate about targeted nanoparticle therapy 
strategies failing to enter clinics. Among the reasons authors claim for this lack of 
translation of targeted therapies are the use of insufficient mouse models for pre-
cise in vivo testing of nanoparticle-based therapies and restriction of targeting by 
wrong administration of the nanoparticles (Bolukbas & Meiners, 2015; Lammers 
et al., 2012; Wilhelm et al., 2016). Accordingly, we designed an in vivo approach 
which addresses these shortcomings: 
Many of the tumor models used for testing active nanoparticle-based targeting 
approaches do not represent the actual tumor development and physiology. 
Flank tumor models or lung metastasis models for example do not resemble the 
anatomical, biological and biochemical structure of lung cancer, thus a sufficient 
evaluation of a targeted therapy approach is hampered (Lammers et al., 2012; 
Wilhelm et al., 2016). In our study we addressed this problem by using the K-ras 
mutant mouse model giving a more physiological image of lung cancer develop-
ment and constitution (Johnson et al., 2001). Hence, our experimental in vivo 
setup reduces misinterpretation of data and active targeting of the CCR2-
targeting MSNs can be evaluated in detail.  
In addition, unsuitable administration of the particles for the treatable tumor site 
is often regarded as another reason for the failure to translate targeted therapy 
approaches from bench to bedside. As an example, intra venous (i.v.) administra-
tion may not always be the fitting application route (Wilhelm et al., 2016). Cheng, 
Tietjen, Saucier-Sawyer, and Saltzman (2015) stress the importance of anatom-
ically targeting the wanted organ to reduce unintended uptake of nanoparticles 
by bystander cells. We therefore used intratracheal delivery of CCR2-targeted 
MSNs to obtain maximal and local loading in our organ of interest, i.e. the lung. 
This approach has already been used by other preclinical and clinical studies 
resulting in lower systemic toxicity and higher accumulation of the therapeutic 
drug in the organ of choice (Mangal, Gao, Li, & Zhou, 2017; Zarogoulidis et al., 
2012). Our data confirms the importance of a local delivery, as we did not observe 
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an enhanced systemic particle uptake in the spleen, liver or kidney, which has 
been an issue with many nanoparticle-based targeted therapy strategies before 
(Bertrand & Leroux, 2012; Yu & Zheng, 2015; Zhang, Poon, Tavares, McGilvray, 
& Chan, 2016).  
However, one can not rule out local toxicity effects when giving nanoparticles 
directly into the lung, as previous studies showed an increase in acute and 
chronic lung damage such as bronchitis and bronchial wall thickening after inha-
lation of nanoparticles (Bolukbas & Meiners, 2015; Mangal et al., 2017; 
Zarogoulidis et al., 2012). Nonetheless the MSNs we used here did not induce 
any major inflammatory responses in previous studies of our lab (S. H. van Rijt 
et al., 2016), thus supporting the use of the intratracheal administration to en-
hance tumor-cell specific targeting. 
 
5.2 Nanotherapeutic approaches need to be carefully validated 
in vivo 
As mentioned above, we confirmed the cell-specific uptake of CCR2-targeted 
MSNs in vitro but failed to observe cell-specific targeting in vivo. In particular, 
when giving the nanoparticles intratracheally into the lungs of K-ras mutant mice, 
tumor-specific targeting of CCR2-targeted MSNs was not observed but alveolar 
macrophages encapsulated targeted as well as non-targeted MSNs to a similar 
extent (Figure 4-19). Our results stress the importance of evaluating targeted 
therapy strategies on a cellular level and not only total tissue uptake of nanopar-
ticles, as the failure of the active targeting approach would have been missed. 
This accords well with previous claims for a more precise and detailed analysis 
of active targeting approaches on a cellular resolution level (Bolukbas & Meiners, 
2015; Wilhelm et al., 2016).  
Several causes could explain the failure of targeted delivery of CCR2-targeted 
MSN. As stated before, we reduced misinterpretation of data due to the fact that 
we used a valid lung cancer mouse model and enhanced tumor specific targeting 
by administering the MSNs directly to the lungs. However, we did not rule out 
impediment of the targeting approach by protein corona formation around the 
nanoparticles. As nanoparticles interact with proteins in vivo, previous studies 
Discussion 
  71 
suggest this mechanism shields targeting ligands or enhances uptake of nano-
particles by phagocytic cells due to opsonizing of the particles by specific proteins 
(Salvati et al., 2013; Tenzer et al., 2013; Walkey et al., 2014). However, protein 
corona formation also occurs in vitro (Tenzer et al., 2013; Walkey et al., 2014), 
thus it does not fully explain the failure of the CCR-targeting MSNs approach in 
vivo.  
Another reason for an insufficient active targeting therapy approach could be the 
choice of an inadequate target (Bolukbas & Meiners, 2015; Wilhelm et al., 2016). 
Nonetheless, we could confirm the overexpression (Figure 4-1) and thus potential 
targeting function of the CCR2 receptor in preclinical lung cancer models and 
human lung cancer samples (Cortez-Retamozo et al.; Fridlender et al., 2011; 
Hiratsuka et al., 2013; Qian et al., 2011; Schmall et al., 2015). Moreover, several 
studies have demonstrated that depletion and targeting of the CCR2 receptor 
reduces tumor growth in preclinical models of lung cancer, lung metastasis, lym-
phoma and pancreatic cancer (Fridlender et al., 2011; Leuschner et al., 2011; 
Marazioti & Stathopoulos, 2014; Mitchem et al., 2013; Roblek et al., 2016). 
Hence, the used receptor can be regarded as a suitable target for the nanoparti-
cle-based therapy approach.  
In addition, satisfactory tumor targeting can be restricted by high intratumoral 
pressure (Heldin, Rubin, Pietras, & Östman, 2004) and extracellular matrix con-
formation hindering particle penetration of the tumor (Cheng et al., 2015; Jain & 
Stylianopoulos, 2010; Nichols, Sakurai, Harashima, & Bae, 2017). While this is 
not a specific limit to an active targeting approach, our data indicates that our 
MSNs indeed only insufficiently penetrated dense tumor tissue while being able 
to reach smaller and less dense tumor lesions (Figure 4-17), in which intratumoral 
pressure end extracellular matrix formulation may not be fully developed.   
Further, the clearance of nanoparticles by alveolar macrophages can restrict suf-
ficient tumor targeting when administering targeting particles directly to the lung 
(Chung et al., 2017; S. H. van Rijt et al., 2016; Woods et al., 2015). Inhalative 
lung cancer therapy induces alveolar macrophage phagocytic responses and in-
creases their number in the local tissue, thus enhancing nanoparticle clearance 
(Forbes et al., 2014). Our data emphasizes the clearing role of alveolar macro-
phages in nanoparticle-based therapy strategies for lung cancer. As our targeted 
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and non-targeted particles were taken up by these phagocytic cells to a similar 
high extent, a receptor mediated uptake of CCR2-targeted nanoparticles can be 
ruled out. Further, alveolar macrophages incorporated a high number of MSNs, 
giving the impression of this being the predominant up-taking cell line. 
However, recent studies suggest using these properties of macrophages to effi-
ciently target the tumor. They propose loading macrophages with drug-carrying 
nanoparticles and taking advantage of their ability to migrate deeper into the tu-
mor tissue, thus transporting the therapeutics to the target site (Andón et al., 
2017). In addition, re-educating tumor-associated macrophages or inhibiting 
TAM-recruitment to the tumor with the help of nanoparticles are also current re-
search topics (Andón et al., 2017). In conclusion, these ideas are showing a pos-
sible use of the phagocytic function of macrophages for future tumor targeting 
strategies.  
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6 Conclusion 
Evaluation of the CCR2-targeted mesoporous silica nanoparticles for lung cancer 
therapy revealed some distinct features. Firstly, the importance of the CCR2 re-
ceptor in lung cancer and the possibility of this receptor to act as a target for 
nanoparticle-based therapies was confirmed. Secondly, a clear difference in the 
results of the in vitro and ex vivo experimental setup was observed. While the 
targeted therapy approach was validated in vitro, the targeting capacity was lost 
in the in vivo approach. Thus, our study emphasizes the importance of a clear 
evaluation of targeted therapies on a cellular level, as the loss of targeting spec-
ificity became only evident when having a closer look at the up-taking cells in 
vivo. Our study stresses the function of alveolar macrophages in the clearance 
process of nanoparticles delivered directly to the lung. This function should be 
further analyzed in the future, as it can also be used for treating tumor-associated 
macrophages or other diseases in which macrophages play an important role.  
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BCA Bicinchoninic acid assay 
BRAF V-Raf murine sarcoma viral oncogene homolog B 
CCL18 C-C motif chemokine ligand 18 
CCL2 C-C motif chemokine ligand 2 
CCL9 C-C motif chemokine ligand 9 
CCR2 C-C chemokine receptor type 2 
CD68 Cluster of differentiation 68 
CDK6 Cell division protein kinase 6 
CEA Carcioembryonic antigen 
CK5/6 Cytokeratine 5 and 6  
COPD Chronic obstructive pulmonary disease 
CSF1 Colony stimulating factor 
CT Computer tomography 
DAPI 4′,6-Diamidin-2-phenylindol 
DDR2 Discoidin domain-containing receptor 2 
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DMSO  Dimethyl sulfoxide 
DTT Dithiothreitol 
ECL Electrochemiluminescence 
ECM Extra cellular matrix 
EDTA Ethylenediaminetetraacetate 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor  
EPR Enhanced permeability and retention 
FBS Fetal bovine serum 
FCS Fetal calf serum 
FGF Fibroblast growth factor 
FGFR1 Fibroblast growth factor receptor 1 
FGFR2 Fibroblast growth factor receptor 2 
FGFR3 Fibroblast growth factor receptor 3 
GM-CSF Granulocyte-macrophage colony stimulating factor 
H&E Hematoxylin and Eosin 
HER2 Receptor tyrosine-protein kinase erbB-2 
HRCT High resolution computer tomography 
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HRP Horseradish peroxidase 
IF Immunofluorescence 
IHC Immunohistochemistry 
IgG Immunoglobulin G 
IL10 Interleukine 10 
IL3 Interleukine 3 
IL4 Interleukine 4 
K-ras Kirsten rat sarcoma viral oncogene homolog 
LHRHR luteinizing hormone releasing hormone receptor 
LKb1 Liver kinase b 1 
MMPs Matrix metalloproteinases 
MRI Magnetic resonance imaging 
MSNs Mesoporous silica nanoparticles 
NSCLC Non-small cell lung cancer 
p53 Tumor suppressor p53 
PBS  Phosphate buffer solution 
PD-1 Programmed cell death protein 1 
PDL-1 Programmed cell death ligand 1 
PEG Polyethylene glycol 
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PET Positron emission tomography 
PIK3 Phosphatidylinositol 3-kinase 
PIK3CA Phosphatidylinositol 3-kinase catalytic subunit 
RIPA Radioimmunoprecipitation assay 
RPM Revolutions per minute 
RPMI Roswell Park Memorial Institute medium 
SCC Squamous cell carcinoma 
SCLC Small cell lung cancer 
SDS Sodiumdodecylsulfate 
SEM Standard error of the mean 
SHS second hand smoke 
TAMs Tumor-associated macrophages 
TBS Tris-buffered saline 
TGF-beta transforming growth factor beta 
TP53 Tumor protein 53 
TTF1 Thyroid transcription factor 1 
VEGF Vascular endothelial growth factor 
WB Western blot 
WT Wild type 
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